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ABSTRACT
To assess non-inferiority of an experimental product to an active control in a clini-
cal trial, an ideal design is to include a placebo arm to ensure both the experimental
product and the active control is superior to placebo. We aim to identify methodol-
ogy to control Type I error rate and maintain adequate power in a superiority/non-
inferiority seamless clinical trial defined as:
1. selecting the best experimental treatment dose vs. placebo out of multiple
treatment doses in Stage I; and
2. assessing non-inferiority of the chosen experimental dose to an active control,
after adding subjects to yield adequate power for non-inferiority, in Stage II.
The trial design here is an antihypertensive trial with change in systolic blood
pressure as the outcome. The trial has three experimental treatment doses arms of
experimental, a placebo control arm, and an active control arm. A simulation study
of 20,000 such trials was conducted. We apply multiple comparison methodologies
in Stage I to detect the most beneficial experimental treatment dose versus placebo,
and test non-inferiority of the selected experimental dose to the active control in
Stage II. Simulated Type I error rate and power for claiming non-inferiority are
vi
calculated for various dose-response trends. The need to adjust alpha to control
Type I error either stage is assessed, seeking the optimal approach for doing so.
Next, type I error and power for various fixed and variable non-inferiority mar-
gins are evaluated, exploring a range of margins informed by the first stage results
of the study. A variable non-inferiority margin informed completely by the first
stage of the trial approach results in inflated error rate which cannot be controlled
by suggested multiplicity adjustments. We assess a synthesis approach between
the fixed and variable margins, to both control the family-wise error rates and
reach adequate power, depending on a tuning parameter defined in our work.
We conclude that well-designed and adequately controlled seamless
superiority/non-inferiority trials are possible with appropriate multiple compar-
isons adjustments and could result in less development time and fewer subjects
needed to assess efficacy than separate trials.
vii
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1CHAPTER 1
Introduction
Clinical trials conducted on medical products pre-market approval in the United
States are broadly split into three phases: Safety (phase I), Learning (phase II), and
Confirmatory (phase III). These trials are implemented consecutively, with a plan-
ning, execution, and analysis phase. This traditional approach is time, money, and
subject intensive. Over recent decades adaptive clinical trial design has sought
to lessen the financial and temporal burden of these trials through innovative de-
signs taking advantage of fewer subjects, less time, or increased power (Stallard
& Todd, 2011). One such adaptive approach, specifically seamless trial designs,
seek to combine into one trial what classically would take two trials. Usually in
the seamless setting, the learning and confirmatory (phase II and phase III) trials
are combined into one. This design may minimize some of the temporal and fi-
nancial burden associated with running two separate clinical trials, and may bring
effective drugs to market earlier.
We define a seamless superiority/non-inferiority clinical trial as one where the
first stage (the learning/phase II stage) is to find the most superior dose of an ex-
perimental treatment as compared to placebo, followed by the second stage (confir-
matory/phase III) consisting of a non-inferiority assessment of the most superior
dose to an active control. As an example for this dissertation, we investigate a trial
where there are three experimental dose arms, one placebo control arm, and one
active control arm with a continuous outcome.
In Chapter Two, we seek to determine the best analytical course for a seamless
superiority/non-inferiority trial, where in the learning/phase II stage, we compare
various experimental product doses to placebo, and in the non-inferiority phase,
2we assess non-inferiority of the winning dose to an active control using a fixed non-
inferiority margin pre-specified in the protocol. In Chapter Three, we consider a
variable non-inferiority margin informed by the first stage of the trial. In Chapter
Four, we define and assess a new non-inferiority margin synthesizing the fixed a
priori hypothesis non-inferiority margin with the variable non-inferiority margin
defined from within-study results.
3CHAPTER 2
Type 1 Error and Power Considerations in Fixed Non-Inferiority Margin
Seamless Superiority/Non-Inferiority Clinical Trials
2.1 INTRODUCTION
In a seamless trial design, subjects are rolled over from the first stage (phase II)
to the second stage (phase III), after making a decision according to pre-specified
rules after Phase II, dictating some aspect (e.g. samples size, desired dose group)
of the Phase III design, based on the data gathered in the Phase II part of the trial
(Bretz et al., 2006). Both a superiority framework in both stages (Kimani et al., 2009;
Schmidli et al., 2006) and a non-inferiority framework in both stages (Schmidli
et al., 2006) have been well defined in the literature. We seek to determine the
best analytical approach for a seamless superiority to placebo and non-inferiority
to active control trial, controlling type 1 error and maximizing power.
Schmidli et. al. (2006) describe a seamless superiority Phase II/III clinical trial
designed to assess multiple experimental treatments compared to a placebo control
group over two stages. After the first stage (the Phase II stage), primary efficacy
and safety are assessed. The study is only stopped for futility, and otherwise con-
tinues on to the second stage. After the interim (post first-stage) analysis, the best
dose (defined as the one with the most favorable risk/benefit ratio) is selected, re-
gardless of statistical significance, and is moved onward to the second stage. There
may also be a sample size re-estimation for the second stage (Phase III) based on
observed effects as compared to initial effect size assumptions used to power the
study at the protocol design stage. At the final analysis, using data from the se-
lected dose group and control group from both stages, they apply the closure prin-
4ciple using combination tests to assess each intersection hypothesis involving the
selected dose group.
A non-inferiority seamless design is discussed by Schmidli et. al. (2006) where
in the first stage of the design two different treatment regimens of an investiga-
tional drug are compared to an existing treatment in a non-inferiority framework.
They use prior knowledge to define the study parameters, such as assumed effect
sizes, standard deviations, and the non-inferiority margin. The study is designed
such that the additional subjects enrolled for the second stage provided adequate
power for the final analysis. At the interim, the treatment with the lower non-
inferiority p-value vs. the active control, regardless of statistical significance, is
selected to continue forward to the second stage and the final non-inferiority anal-
ysis takes place at the end of the trial. The p-values from the first and second stage
are assessed in the closed testing procedure (Bretz et al., 2006).
Neither of the aforementioned designs require significance at the first stage,
only at the final stage. Also, the form of the hypothesis does not change from
stage to stage- a superiority trial maintains a superiority null hypotheses in stages
one and two, while a non-inferiority trial maintains a non-inferiority null hypoth-
esis in both stages. We propose an innovative trial design which requires signif-
icance in both stages one and two, and explores two separate questions of inter-
est in one trial: superiority of an experimental treatment vs. placebo control and
non-inferiority of the experimental treatment to an active control. We will explore
this setting in a five-arm trial, with three experimental treatments dose arms, one
placebo control arm, and one active control arm. Prior to assessing superiority of
the experimental treatment doses to placebo control, we evaluate assay sensitivity
by testing that the active control arm is significantly better than the placebo control
5arm. This ensures that there is an effect of the active control treatment as compared
to placebo control, and the potential effect of an experimental treatment arm can be
appropriately assessed in relation to non-inferiority to the active control. If there
is no significant active control effect, finding an experimental treatment dose to be
non-inferior to the active control does not provide clinically relevant information.
In the first stage, we have three hypotheses of interest, comparing each experi-
mental treatment dose to the placebo control in a superiority framework. In the
second stage, there is one hypothesis of interest, comparing the winning experi-
mental treatment dose from the first stage to the active control in a non-inferiority
framework. Only one experimental treatment dose needs to be found significant
in the first stage to move forward, and then must be found significant in the sec-
ond for success in the trial. Patients from the selected experimental treatment dose
in the first stage are carried forward and used in the non-inferiority stage. It is
important to show a significant beneficial superiority effect of experimental treat-
ment vs. placebo control in the first stage in this setting in order to determine the
experimental treatment is at least efficacious on its own.
2.2 MOTIVATING STUDY BACKGROUND
This project was motivated by a real-life clinical trial of an anti-hypertensive med-
ication. The design was proposed as follows: there were three experimental treat-
ment doses in question that the sponsor wanted to compare with a placebo control
in a superiority framework, and then compare with an active control in a non-
inferiority framework. At the time of the study design, it was unclear what the
correct analytical approach would be. In the study design stage, the sponsor, based
on previous trials and clinical knowledge of their product, set the assumed effects
6of the placebo control as a 5 millimeters of mercury (mmHg) mean decrease in sys-
tolic blood pressure (sbp), and the active control with a 10 mmHg mean decrease
in sbp, and the experimental treatment doses having a hypothesized effect of a
similar mean 10 mmHg decrease in sbp. The standard deviation was assumed to
be 10 for each group, and the non-inferiority margin in the second stage was set at
1.5 mmHg.
To be considered successful, the trial needed to find at least one experimental
treatment dose significantly better than the placebo control in the first stage, and
then find that same experimental treatment dose to be significantly non-inferior
to the active control. This mimics the set-up of two separate trials, though would
be conducted in one overall trial. The benefit of the seamless design over two
separate trials in this setting is that patients in the chosen experimental treatment
dose group in the first stage are included in the final analyses in the second stage,
thereby resulting in a reduced sample size compared to the traditional approach.
In a traditional seamless design, the first stage does not necessarily call for sig-
nificance, and the testing paradigm (either superiority or non-inferiority) remains
the same from the first to second stage. The original motivating study ended up
split into two separate trials- a Phase II exploratory trial, followed by a Phase III
confirmatory trial. However, we assess options for multiplicity adjustments which
could be utilized to control family-wise error in our novel study design.
2.3 METHODS
As the first stage of our design involves testing superiority of multiple (3) doses of
the investigational product to a placebo group, we consider the effect of multiple
testing on the Type 1 error of the study. There are three significance tests being
7carried out, only one of which needs to be significant to continue with the second
stage of the study.
Type 1 error is the chance of falsely rejecting a true null hypothesis. In statistical
analysis, we set an acceptable level of error for this probability, denoted by α. The
family-wise error rate (FWER) of a study is the probability of making at least one
type 1 error in a family of hypotheses. When k null hypotheses in one set of data
are tested simultaneously at a full α-level, this can lead to an inflation of the FWER
rate of the study, which can be as large as:
1− (1− α)k > α
This formula represents the maximum probability of at least one false rejection.
In general the family-wise error rate ranges between the nominal α level and the
formula above. To account for this inflation, there have been a number of methods
developed to control the family-wise error of the study in the presence of multiple
hypothesis testing.
In our trial, in the first (superiority) stage we have three sets of null and alter-
native hypotheses of interest (below); µ represents the true (theoretical) mean of
each experimental arm.
H01 : µDose 1 ≤ µPlacebo
H11 : µDose 1 > µPlacebo
H02 : µDose 2 ≤ µPlacebo
H12 : µDose 2 > µPlacebo
H03 : µDose 3 ≤ µPlacebo
H13 : µDose 3 > µPlacebo
8Testing each of these hypotheses at a nominal one-sided alpha level of 0.025 could
result in an inflated one-sided family-wise error rate as great as:
1− (1− 0.025)3 = 0.0731 > 0.025
To control the family-wise error rate in the superiority stage, we can utilize a mul-
tiplicity adjustment.
In the second stage of our trial, we have one hypothesis of interest compar-
ing the most significant dose from the first stage to the active control in a non-
inferiority context with a non-inferiority margin of 1.5 mmHg:
H0 : µDose S − µActive Control ≥ 1.5
H1 : µDose S − µActive Control < 1.5
Though there is only one hypothesis to be tested at the second stage of the
trial, due to the multiple hypotheses in the trial overall, we have to ensure that
the family-wise error rate of the trial overall is controlled at the nominal alpha
level of significance. The FWER of the trial overall is the chance of claiming that
a dose is both superior to placebo and is also non-inferior to the active control
when it is truly inferior to the active control. Note that at least one superiority null
hypothesis and the non-inferiority null hypothesis need to be rejected for the study
to be successful. We review two common approaches to multiplicity adjustment
here.
92.3.1 Multiplicity Adjustments
2.3.1.1 Bonferroni Adjustment
The Bonferroni correction divides the full alpha by the number of hypotheses to
be tested (denoted as n), and tests each individual hypothesis at the α
n
level of
significance. This strongly controls the type 1 error of the study overall (Dunn,
1961). This is known to be a conservative approach (i.e., family-wise error rate is
usually less than the nominal chosen level α).
2.3.1.2 Hochberg Adjustment
The Hochberg method controls the false discovery rate in a study with multiple
testing. The false discovery rate (FDR) is the proportion of incorrect rejections
of the null hypothesis out of all rejections of the null hypothesis. However, in a
clinical trial with few hypotheses tests, the Hochberg approach controls the FWER
across multiple nulls.
Each of the p-values corresponding with each hypothesis to be tested are or-
dered in ascending order p(1), . . . , p(n), and the largest p-value p(n) is tested at α, if
p(n) ≤ α, then all the null hypotheses are rejected. If not, then the corresponding
H(n) fails to be rejected, and the next ordered p-value, p(n−1), is compared to 12α.
If H(n−1) is rejected, then all the remaining hypotheses are as well, if not, then the
process continues comparing p(n−2) to 13α, etc (Hochberg & Benjamini, 1995).
2.3.2 Assay Sensitivity
It is important to determine assay sensitivity in a non-inferiority trial. That is, we
must ascertain whether or not the active control effect is as expected in the plan-
10
ning stage. Without knowing this, we cannot know if a significant non-inferiority
trial indicates that both the active control and the experimental treatment are ef-
fective, or if both are ineffective (D’Agostino et al., 2003).
Assay sensitivity traditionally is determined from "historical evidence of sen-
sitivity to drug effects" and "appropriate trial conduct" (ICH, 2000). Historical ev-
idence is taken from similarly designed past trials of the active control. These
past trials can be on the specific active control used in the study, or other treat-
ments with comparable effects, but must be in the specific therapeutic area of the
new trial. Appropriate trial conduct is evaluated after the conclusion of the non-
inferiority study, and takes into account factors such as similar design, comparable
study population entered, and compliance (ICH, 2000).
2.4 SIMULATION STUDY
2.4.1 Parameters
We performed a simulation study to numerically calculate the family-wise error
rate of the study, as well as the power, under 9 data configurations, using 5 differ-
ent multiplicity adjustment paradigms. The family-wise error rate of the study is
the probability of finding a truly inferior to active control experimental treatment
dose to be the most significantly better than placebo dose, as well as significantly
non-inferior to the active control. It is defined as follows:
FWER = P

P
 x¯D1 − x¯Pl
s
(√
1
nD1
+ 1nPl
) > t1−α,nD1+nPl−2
 < α1
⋂
P
 x¯D1 − x¯AC −M
s
(√
1
nD1
+ 1nAC
) > t1−α,nD1+nAC−2
 < α2
⋂
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 x¯D1 − x¯Pl
s
(√
1
nD1
+ 1nPl
) > t1−α,nD1+nPl−2
 < P
 x¯D2 − x¯Pl
s
(√
1
nD2
+ 1nPl
) > t1−α,nD2+nPl−2
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nD3
+ 1nPl
) > t1−α,nD3+nPl−2
⋃
P
 x¯D2 − x¯Pl
s
(√
1
nD2
+ 1nPl
) > t1−α,nD2+nPl−2
 < α1
⋂
P
 x¯D2 − x¯AC −M
s
(√
1
nD2
+ 1nAC
) > t1−α,nD2+nAC−2
 < α2
⋂
P
 x¯D2 − x¯Pl
s
(√
1
nD2
+ 1nPl
) > t1−α,nD2+nPl−2
 < P
 x¯D1 − x¯Pl
s
(√
1
nD1
+ 1nPl
) > t1−α,nD1+nPl−2
⋂
P
 x¯D2 − x¯Pl
s
(√
1
nD2
+ 1nPl
) > t1−α,nD2+nPl−2
 < P
 x¯D3 − x¯Pl
s
(√
1
nD3
+ 1nPl
) > t1−α,nD3+nPl−2
⋃
P
 x¯D3 − x¯Pl
s
(√
1
nD3
+ 1nPl
) > t1−α,nD3+nPl−2
 < α1
⋂
P
 x¯D3 − x¯AC −M
s
(√
1
nD3
+ 1nAC
) > t1−α,nD3+nAC−2
 < α2
⋂
P
 x¯D3 − x¯Pl
s
(√
1
nD3
+ 1nPl
) > t1−α,nD3+nPl−2
 < P
 x¯D1 − x¯Pl
s
(√
1
nD1
+ 1nPl
) > t1−α,nD1+nPl−2
⋂
P
 x¯D3 − x¯Pl
s
(√
1
nD3
+ 1nPl
) > t1−α,nD3+nPl−2
 < P
 x¯D2 − x¯Pl
s
(√
1
nD2
+ 1nPl
) > t1−α,nD2+nPl−2


Where x¯i is the sample mean of arm i, ni is the sample size of arm i, α1 is the
nominal alpha level for the superiority stage test, α2 is the nominal alpha level
for the non-inferiority stage test, M is the non-inferiority margin, ni is the sample
size of arm i, and s is the square root of the pooled sample variance, defined as:
s2 = [(n1−1)s1+(n2−1)s2]
n1+n2−2 , where n1, n2 are the sample sizes in each of the 2 arms being
compared, and s1, s2 are the respective sample variances.
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The power of the study was calculated as the likelihood of finding a truly non-
inferior to active control experimental treatment dose to be the most significantly
better than placebo and to be non-inferior to active control.
The fixed non-inferiority margin, M1 set at the design stage, is calculated as
µActive Control−µPlacebo. M2 is a smaller non-inferiority margin, which is a function of
M1
M2 = rM1
where r is a clinical-reasoning driven proportion. We set M2 as half of M1: M2 =
1
2
M1. The result is M1 = 3 mmHg and M2 = 1.5 mmHg, and M2 is the non-
inferiority margin used in analysis (FDA (CDER), 2016).
2.4.2 Data Generation
We generated 10,000 datasets for each configuration of scenario and multiplic-
ity adjustment, encompassing the possible combinations of true superiority to
placebo, true inferiority to placebo, true non-inferiority to active control, and true
inferiority to active control over the three experimental dose possibilities. Based on
the motivating study parameters, the placebo group was simulated from a popula-
tion with a mean decrease from baseline of 5 mmHg, and the active control group
was generated from a population with a mean decrease from baseline of 8 mmHg.
The non-inferiority margin was set at 1.5 mmHg, half the difference between the
placebo and active control group effects. Therefore, the mean experimental dose
effects were varied from -5 mmHg, -6.5 mmHg, to -8 mmHg (See Table 2.1)
In simulation scenarios C1-C4, the data generation assumptions correspond
with a variation of overall null hypotheses; that is, none of the doses are truly
non-inferior to the active control. C1 corresponds to a null hypothesis for the su-
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periority to placebo test, where all of the doses are truly equal to placebo. C4 cor-
responds to a null hypothesis for the non-inferiority to the active control test, all of
the doses are superior to the placebo but, for each dose, the mean difference versus
active control from which the simulations are generated, has a mean equal to the
active control effect minus the non-inferiority margin. C2 and C3 have one or two
dose means equal to placebo means, and one or two doses where the difference in
means versus active control is equal to the non-inferiority margin boundary as in
C4.
In C5-C9, the data generation assumptions correspond to variations of alterna-
tive hypotheses. C5-C7 have one dose truly non-inferior to the active control, and
have one to two doses equal to placebo or on the non-inferiority margin boundary
as in C4. C8 and C9 have two doses truly non-inferior to the active control; C8’s
third dose being equal to placebo, while C9’s third dose is on the non-inferiority
margin boundary. These various conditions allow us to cover the range of com-
binations of null and alternative hypotheses to see how the family-wise error and
power changes over the different possible true dose combinations.
The null hypothesis for superiority and for non-inferiority can not be simu-
lated simultaneously. A null hypothesis for superiority is simulated by setting the
dose equal to the placebo, while a null hypothesis for non-inferiority is simulated
by setting the dose equal to the active control minus the non-inferiority margin.
Therefore, we include a range of conditions that simulate a null hypothesis, and a
range of conditions to simulate potential alternative hypothesis.
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Table 2.1: Data Simulation Parameters: Mean Changes from Base-
line; Standard Deviation is 10 mmHg within each group
Active
Dose 1 Dose 2 Dose 3 Control Placebo
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
C1 -5 -5 -5 -8 -5
C2 -5 -5 -6.5 -8 -5
C3 -5 -6.5 -6.5 -8 -5
C4 -6.5 -6.5 -6.5 -8 -5
C5 -5 -5 -8 -8 -5
C6 -5 -6.5 -8 -8 -5
C7 -6.5 -6.5 -8 -8 -5
C8 -5 -8 -8 -8 -5
C9 -6.5 -8 -8 -8 -5
The simulation study was conducted using SAS version 9.4 via macro-
language. Data was analyzed via PROC GLM and PROC MULTTEST for the su-
periority testing, and PROC TTEST for the non-inferiority testing.
2.4.3 Powering
PROC POWER is used to calculate sample size. For each type of multiplicity ad-
justment, two sample size calculations were performed: for the first (superiority)
stage of testing and for the second (non-inferiority) stage of testing. We aimed to
power the overall study for the final conclusion of non-inferiority at approximately
80%; if each stage is powered at 90%, then the overall study should be powered at
approximately 80% (90%× 90% ≈ 80%). We use independently powered study as-
sumptions for our framework, and compare the simulated power to this nominal
value.
For the superiority stage of testing, the unadjusted analyses sample size was
calculated with a one-sided alpha of 0.025, 95% power, with a common standard
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deviation of 10 mmHg in each group, and group means of -5 mmHg and -8 mmHg,
yielding a necessary 290 subjects per group. For adjusted analysis, the sample
size was calculated with a Bonferroni-corrected one-sided alpha of 0.00833 (0.025
3
=
0.00833), 95% power, with a standard deviation of 10 mmHg, and group means of -
5 mmHg and -8 mmHg, yielding a necessary 364 subjects per group. We power the
assay sensitivity test at 95%, so that the overall stage one power was approximately
90% (95%× 95% ≈ 90%).
For the non-inferiority stage of testing, the unadjusted analyses sample size was
calculated with a one-sided alpha of 0.025, 90% power, with a standard deviation
of 10 mmHg, group means of -8 mmHg and -8 mmHg, and a non-inferiority mar-
gin of 1.5 mmHg. This yielded a required sample size of 935 subjects per group.
For adjusted analyses, the sample size was calculated with a Bonferroni-corrected
one-sided alpha of 0.00833. We use this adjusted alpha because if in the first stage
only one experimental dose arm of the three experimental dose arms is found to
be significantly better than placebo, according to the theory of the Bonferroni ad-
justment, only 1
3
of the alpha can be used to test the second stage. Therefore, we
would have 0.00833 for the final analysis in the worst case scenario. We use 90%
power, with a standard deviation of 10 mmHg, and group means of -8 mmHg and
-8 mmHg, with a non-inferiority margin of 1.5 mmHg for the sample size calcula-
tion; under these circumstances, we require 1203 subjects per group. These results
are summarized in Table 2.2.
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Table 2.2: Data Simulation Parameters: Sample Size
Stage One Stage Two Stage One Stage Two
Adjustment Adjustment Sample Size Sample Size
Unadjusted Unadjusted 290 935
Bonferroni Unadjusted 364 935
Bonferroni Bonferroni 364 1203
Hochberg Unadjusted 364 935
Hochberg Bonferroni 364 1203
2.4.4 Analytical Process
In addition to conducting superiority testing of the experimental treatment versus
placebo in stage 1, we employed an assay sensitivity test in order to ensure that the
active control led to a significantly larger decrease in sbp compared to the placebo,
with the below hypotheses.
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
If we cannot show that the active control has an effect over the placebo, then show-
ing that a dose of the experimental treatment is non-inferior to the active control
does not give any meaningful information about its effect, rendering the entire
study meaningless. To avoid incurring temporal, financial, and clinical burdens
for study participants and sponsors, we perform this test before moving forward
with analysis. (Temple, 2008)
Once each simulated study was shown to have significant evidence that the
active control was better than the placebo, each dose was compared with placebo
individually. The hypotheses are below.
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
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i ∈ (1, 2, 3)
Each study was then tested using one of the adjustment paradigms discussed be-
low. If one or more doses were found to be significantly better than placebo in
decreasing sbp, then the most significant dose was moved forward to the second
stage of testing. This most significant dose was tested in a non-inferiority frame-
work as compared to the active control (Blackwelder, 1982) (below); the δ repre-
sents the non-inferiority margin for the hypothesis test:
H0 : µDose S − µActive Control ≥ δ
H1 : µDose S − µActive Control < δ
At this point both error and power were calculated for the overall study.
Superiority 
Test
Assay 
Sensitivity 
Test
Dose One
Dose Two
Dose Three
Placebo
Active 
Control
Dose Three v. Placebo
Dose Two v. Placebo
Dose One v. Placebo
Active Control  v. 
Placebo
Add 
Subjects
Randomize 
to 5 Arms
Stage One
Dose Three 
(WLOG)
Active 
Control
Non-
Inferiority 
Test
Stage Two
Figure 2.1: Study Process
2.4.5 Adjustment Methodologies
We explored unadjusted analyses, Bonferroni adjusted analyses, and Hochberg
adjusted analyses. The goal was to find the best combination of adjustments which
would control the family-wise error rate, while giving the highest power. We used
the following six adjustment schema:
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• Unadjusted in stage one, Unadjusted in stage two
• Bonferroni adjusted in stage one, Unadjusted in stage two
• Bonferroni adjusted in stage one, Bonferroni adjusted in stage two
• Hochberg adjusted in stage one, Unadjusted in stage two
• Hochberg adjusted in stage one, Bonferroni adjusted in stage two
In the first stage and in the second stage, an unadjusted analysis means that we
did not perform any multiplicity adjustment to the analysis and tested at the full-
alpha level. In the first stage, a Hochberg analysis means we utilized the Hochberg
multiplicity adjustment methodology as described above. For the first stage, a Bon-
ferroni adjustment means that we utilized the Bonferroni multiplicity adjustment
methodology as described above. For the second stage, a Bonferroni adjustment
means that we tested at an alpha level depending on how many superiority hy-
potheses were rejected in the first stage, as described below.
2.5 RESULTS
2.5.1 Unadjusted Stage One, Unadjusted Stage Two
First we considered the completely unadjusted analysis of this trial. We begin with
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three in the
first stage at α = 0.025:
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H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
and the non-inferiority hypothesis at α = 0.025
H0 : µDose S − µActive Control ≥ 1.5
H1 : µDose S − µActive Control < 1.5
In C1-C4, the conditions correspond with a variation of overall null hypotheses;
that is, none of the doses are truly non-inferior to the active control. Conditions 5-9
correspond with a variety of alternative hypotheses.
In Table 2.3, we see that the family-wise error rate is controlled in C1, which
corresponds with the superiority null hypothesis. In this case, there is virtually
zero overall type one error. In the first phase, any dose found to be significantly
better than placebo is due to chance and sampling error in that simulation dose and
placebo groups. Therefore, when there is such a dose incorrectly pushed through
to the second stage of testing, for it to be found significantly non-inferior to active
control, the active control group also has to have an unusually low effect in that
specific simulation. The simulation of the placebo group and the active-control
groups are independent. As we test for assay sensitivity before even looking at
dose superiority to placebo, those simulations where the active control group is
unusually ineffective compared to placebo are already eliminated.
The family-wise error rate is controlled in C2 as well, but not in C3 or C4. We
see that the overall error increases as more doses have a larger effect, even a still
inferior to active control effect. As more doses’ true effect is on the non-inferiority
margin, more simulations will move past the first stage of testing correctly being
found to be significantly better than placebo. Then, those doses are tested in a non-
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inferiority setting against the active control. By design there will be a proportion
of simulations found significant by chance, as we are essentially testing the non-
inferiority null hypothesis. However, the overall type 1 error in this context is nat-
urally controlled when there is one dose whose true effect is at the non-inferiority
margin, and the remaining doses have a true effect equal to placebo.
The FWER is inflated in C3 and in C4, which corresponds with the non-
inferiority null hypothesis. When all two or three doses have a true effect that
is equal to the difference of the effect of the active control and the non-inferiority
margin, then the type 1 error is inflated due to multiple testing. We conclude that
a clinical trial with this design does need some adjustment to account for the mul-
tiple testing.
The studies were all designed to be powered at approximately 80%, and we see
that the simulated power is about as expected. It is slightly lower than expected in
C7.
2.5.2 Bonferroni Stage One, Unadjusted Stage Two
Here we considered an analysis with a Bonferroni correction in the superiority
stage, and an uncorrected analysis in the non-inferiority stage. First we conducted
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three in the
first stage at α = 0.00833:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
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i ∈ (1, 2, 3)
and the non-inferiority hypothesis at α = 0.025
H0 : µDose S − µActive Control ≥ 1.5
H1 : µDose S − µActive Control < 1.5
We see in Table 2.3 that the FWER is very similar to the completely unadjusted
analysis. If these two stages were split into two separate trials, this methodology
would widely be applied in practice. The phase II trial with three doses would
have a Bonferroni correction, and the phase III trial comparing only one dose to
an active control would be tested with no multiplicity adjustment. However, we
find that a Bonferroni correction in the first stage of testing alone is not sufficient
to strongly control the family-wise error rate of the study overall.
We see that applying a Bonferroni correction to the first stage of testing in-
creases the overall power of the study under all of the conditions. The sample size
calculations indicate an expected power of approximately 80% overall, but with
this adjustment we see simulated power between 82.36% and 91.94%.
2.5.3 Bonferroni Stage One, Bonferroni Stage Two
Here we considered an analysis with a Bonferroni correction in the superiority
stage, and a Bonferroni corrected analysis in the non-inferiority stage. First we
conducted an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three in the
first stage at α = 0.00833:
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H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
If all three of the doses were found to be significantly better than placebo, then the
non-inferiority hypothesis (below) was tested at the full α = 0.025. If two out of the
three doses were found to be significantly better than placebo, the non-inferiority
hypothesis was tested at α = (2
3
)0.025 = 0.016667. If only one dose was found
to be significantly better than placebo in the first stage, then the non-inferiority
hypothesis was tested at α = (1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥ 1.5
H1 : µDose S − µActive Control < 1.5
This methodology is effective in strongly controlling the FWER- we see in Ta-
ble 2.3 that the highest error of any condition in the trial is 1.73%. We know that
the Bonferroni adjustment is a good method for controlling the inflation of type 1
error in multiplicity adjustment situations; however it is a more conservative ap-
proach. We see that the power under condition 5 is slightly decreased from the
previous approach where we leave the non-inferiority testing unadjusted; though
is increased from the completely unadjusted analysis. Under all of the other condi-
tions, the power is greater when applying a Bonferroni adjustment to both stages
of testing than when only applying it to the first stage. Though this methodology
is successful in controlling the family-wise error rate, the simulated error rate is
not as close to the nominal alpha level as we would like.
23
2.5.4 Hochberg Stage One, Unadjusted Stage Two
Here we considered an analysis with a Hochberg correction in the superiority
stage, and an uncorrected analysis in the non-inferiority stage. First we conducted
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. Each of the three following hypotheses were
analyzed separately:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Then the resulting p-values were adjusted based on Hochberg’s methodology
(Hochberg & Benjamini, 1995) as follows:
p˜(i) =

p(m) for i = m
min(p˜(i+1), (m− i+ 1)p(i)) for i = m− 1, · · · , 1
and then tested at α = 0.025. Then the non-inferiority hypothesis below was
tested at α = 0.025.
H0 : µDose S − µActive Control ≥ 1.5
H1 : µDose S − µActive Control < 1.5
We see in Table 2.3 that with this approach, the FWER is very similar to the
completely unadjusted approach and the Bonferroni stage one, Unadjusted stage
two approach. The main practical difference we see with utilizing a Hochberg
adjustment in the first stage is an increase in power from an unadjusted approach.
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This methodology mirrors what might take place if this study was designed as two
trials, instead of one seamless trial. The superiority to placebo analysis could be
controlled with a Hochberg correction to account for the multiplicity introduced
by testing three doses against placebo. Then as one dose would move forward
to a new non-inferiority trial against an active control. If that were a separate trial
there would be no multiplicity issue to account for, and could be tested unadjusted.
However, we find that a Hochberg correction in the first stage of testing alone does
not sufficiently strongly control the family-wise error. The simulated power under
this adjustment is very similar to that of the Bonferroni/Unadjusted approach. It
represents an increase in power from the totally unadjusted approach.
2.5.5 Hochberg Stage One, Bonferroni Stage Two
Here we considered an analysis with a Hochberg correction in the superiority
stage, and an uncorrected analysis in the non-inferiority stage. First we conducted
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at a full one-sided α level of 0.025. Each of the three following hypotheses were
analyzed separately:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Then the resulting p-values were adjusted based on Hochberg’s methodology
(Hochberg & Benjamini, 1995) as follows:
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p˜(i) =

p(m) for i = m
min(p˜(i+1), (m− i+ 1)p(i)) for i = m− 1, · · · , 1
and then tested at α = 0.025. If all three of the doses were found to be significantly
better than placebo, then the non-inferiority hypothesis (below) was tested at the
full α = 0.025. If two out of the three doses were found to be significantly better
than placebo, the non-inferiority hypothesis was tested at α = (2
3
)0.025 = 0.016667.
If only one dose was found to be significantly better than placebo in the first stage,
then the non-inferiority hypothesis was tested at α = (1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥ 1.5
H1 : µDose S − µActive Control < 1.5
With this methodology, we find that the FWER is strongly controlled. The high-
est error we see under this adjustment paradigm is 2.09% (see Table 2.3), where we
would accept a maximum error rate of 2.5%. This represents a better utilization of
alpha than the Bonferroni/Bonferroni approach above, where the maximum error
rate was only 1.73%. Though the power under condition 5 is slightly decreased
from the Hochberg/Unadjusted and the Bonferroni/Unadjusted methods above,
under all other conditions this Hochberg/Bonferroni methodology represents the
highest power of all of the adjustments considered. Using a Hochberg correction
in the superiority stage, and a Bonferroni correction in the non-inferiority stage
yields both highest power, a strongly controlled family-wise error rate, and is the
best approach of all those considered for this study design.
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Table 2.3: Simulation Results
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2.6 DISCUSSION
Seamless trial designs have the potential to impact clinical drug development in
myriads of ways. Depending on the specific trial, it may take less time, necessitate
less subjects, or glean information more efficiently. However, before benefiting
from these advances, it is imperative that we ensure the design and analysis plan
are adequately controlling the family-wise error rate of the trial.
We have shown that though this trial design mandates two significant end-
points for success, there is still a need for adjustment. The completely unadjusted
analysis showed an increase in FWER over the nominal alpha-level of 0.025. The
two analytical approaches mirroring the methods used in two separate trials (Bon-
ferroni/Unadjusted and Hochberg/Unadjusted) are also shown to fail to strongly
control the family-wise error rate. This is an interesting finding, as this is consid-
ered robust methodology in separate trials. Possibly the carryover of subjects from
the first to second stage is causing the increase in error due to non-independence
introduced.
We find that there are two methodological approaches that have worked to
control the FWER under these circumstances: a Hochberg correction in the first
stage, followed by a Bonferroni correction to the second or a Bonferroni correction
to both stages of analysis. Both of these methods strongly control the family-wise
error rate. The Hochberg/Bonferroni approach makes more use of the alpha avail-
able, with an error rate of 2.09% v. 1.73% in the Bonferroni/Bonferroni approach.
The power of both approaches is fairly similar.
We recommend using Hochberg corrected p-values when comparing the three
experimental doses to placebo, and using a Bonferroni correction when assessing
the non-inferiority hypothesis. This approach controls the family-wise error rate,
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takes the most advantage of the alpha available, without a loss of power.
2.7 EXAMPLE OF SIMULATION PROCESS FOR CALCULATION OF SIMU-
LATED POWER
In this section, we illustrate how final simulated power is calculated. We use condi-
tion 5 with no multiplicity adjustments in either stage to demonstrate this process.
In Figure 2.1 we see the entire study design process. Each of the 10,000 sim-
ulated datasets is run through this process. After the assay sensitivity test, 493
studies failed to show assay sensitivity (4.93%). This leaves 9507 studies to enter
the superiority testing of stage one. Of these 9507 studies, 114 (1.14% of the orig-
inal 10,000) found dose one to be the most significantly better than placebo dose
in stage one. Dose two was found to be the most significantly better than placebo
dose in 89 studies (.89% of the original 10,000 studies). The remaining 9304 stud-
ies found dose three to be the most significantly better than placebo dose (93.04%
of the original 10,000 studies). Of these 9304 studies, 9072 of them found dose
three to be significantly better than placebo, and therefore moved on to the second
stage (90.72% of the original 10,000 studies). In stage two, 8199 simulations find
dose 3 to be significantly non-inferior to the active control. This corresponds to the
simulated power we calculated of 81.99%, as seen in Table 2.3.
2.8 SIMULATED CLINICAL TRIAL ILLUSTRATIVE EXAMPLE
In this section, we use one simulation of this clinical trial to illustrate our process.
We begin with simulating the data under condition five. Dose one, dose two, and
the placebo arms have a mean effect of -5, dose three and the active control arms
have a mean effect of -8. All arms of the trial have a standard deviation of 10.
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Under the six different analytical paradigms, we have different sample size
requirements, summarized in Table 2.4 below, along with the simulated means for
each arm at the end of stage one.
Table 2.4: Sample Sizes and Simulated Mean Effect Sizes
Active
Adjustment Sample Size Dose 1 Dose 2 Dose 3 Placebo Control
Stage 1 Stage 2 Stage 1 Stage 2 Mean Mean Mean Mean Mean
Unadjusted Unadjusted 290 935 -5.52 -5.32 -7.96 -6.10 -8.19
Bonferroni Unadjusted 364 935 -5.73 -5.40 -7.94 -5.71 -7.98
Bonferroni Bonferroni 364 1203 -5.73 -5.40 -7.94 -5.71 -7.98
Hochberg Unadjusted 364 935 -5.73 -5.40 -7.94 -5.71 -7.98
Hochberg Bonferroni 364 1203 -5.73 -5.40 -7.94 -5.71 -7.98
2.8.1 Unadjusted Stage One, Unadjusted Stage Two
The sample size calculations are based on an unadjusted full 1-sided alpha of 0.025,
at 95% power, yielding n=290 for each arm in the first stage. Using the same alpha,
90% power, and a non-inferiority margin of 1.5, the necessary sample size for the
second stage is n=935 per group. After data simulation, the first step of testing
is to run the assay sensitivity test on the active control and placebo groups with
n=290 in each group. This involves a t-test comparison, ensuring that the active
control is significantly better than the placebo (p = 0.0099) at the α = 0.025 level of
significance.
Once the study passed this step, we move on to the first stage of testing, with
n=290 subjects per group. We find that dose one (p = 0.4714) and dose two (p =
0.3286) are not significantly different from placebo at the α = 0.025 level. Dose
three is found to be significantly better than placebo (p = 0.022) at the α = 0.025
level of significance.
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Dose three moves forward to the second stage of testing, enrolling 645 more
subjects each into the dose three and active control arms for a total of n=935 in
each arm. Dose three is then compared to the active control with a non-inferiority
margin of 1.5 at the α = 0.025 level of significance. We find dose three to be sig-
nificantly non-inferior to the active control (p < 0.0001). This means this trial was
successful, as dose three was found both significantly better than placebo, and
non-inferior to the active control.
2.8.2 Bonferroni Stage One, Unadjusted Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0,025
3
= 0.00833, at 95% power, yielding n=364 for each arm in the first stage. Using
the unadjusted one-sided alpha of 0.025, 90% power, and a non-inferiority margin
of 1.5, the necessary sample size for the second stage is n=935 per group.
After data simulation, the first step of testing is to run the assay sensitivity test
on the active control and placebo groups with n=364 in each group. This involves
a t-test comparison, ensuring that the active control is significantly better than the
placebo (p = 0.0018) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=364 subjects per group. We find that dose one (p = 0.9768) and dose two (p =
0.6746) are not significantly different from placebo at the α = 0.00833 level. Dose
three is found to be significantly better than placebo (p = 0.0022) at the α = 0.00833
level of significance.
Dose three moves forward to the second stage of testing, enrolling 571 more
subjects into both the dose three and the active control arms for a total of n=935
in each. Dose three is then compared to the active control with a non-inferiority
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margin of 1.5 at the α = 0.025 level of significance. We find dose three to be sig-
nificantly non-inferior to the active control (p < 0.0001). This means this trial was
successful, as dose three was found both significantly better than placebo, and
non-inferior to the active control.
2.8.3 Bonferroni Stage One, Bonferroni Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0.025
3
= 0.00833, at 95% power, yielding n=364 for each arm in the first stage. Using
the Bonferroni-adjusted 1-sided alpha of 0.025
3
= 0.00833, 90% power, and a non-
inferiority margin of 1.5, the necessary sample size for the second stage is n=1203
per group.
After data simulation, the first step of testing is to run the assay sensitivity test
on the active control and placebo groups with n=364 in each group. This involves
a t-test comparison, ensuring that the active control is significantly better than the
placebo (p = 0.0018) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=364 subjects per group. We find that dose one (p = 0.9768) and dose two (p =
0.6746) are not significantly different from placebo at the α = 0.00833 level. Dose
three is found to be significantly better than placebo (p = 0.0022) at the α = 0.00833
level of significance.
Dose three moves forward to the second stage of testing, enrolling 839 more
subjects into both the dose three and the active control arms for a total of n=1203
in each. Dose three is then compared to the active control with a non-inferiority
margin of 1.5 at the α = 0.00833 level of significance, because only one dose of the
three tested in the first stage was found to be significant. We find dose three to be
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significantly non-inferior to the active control (p < 0.0001). This means this trial
was successful, as dose three was found both significantly better than placebo, and
non-inferior to the active control.
2.8.4 Hochberg Stage One, Unadjusted Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0.025
3
= 0.00833, at 95% power, yielding n=364 for each arm in the first stage. Using
the unadjusted one-sided alpha of 0.025, 90% power, and a non-inferiority margin
of 1.5, the necessary sample size for the second stage is n=935 per group.
After data simulation, the first step of testing is to run the assay sensitivity test
on the active control and placebo groups with n=364 in each group. This involves
a t-test comparison, ensuring that the active control is significantly better than the
placebo (p = 0.0015) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=364 subjects per group. Then, we adjust the p-values based on the Hochberg
method and compare the adjusted p-values to the full alpha level. We find that
dose one (p = 0.976) and dose two (p = 0.976) are not significantly different from
placebo at the α = 0.025 level. Dose three is found to be significantly better than
placebo (p = 0.0085) at the α = 0.025 level of significance.
Dose three moves forward to the second stage of testing, enrolling 571 more
subjects into both the dose three and the active control arms for a total of n=935
in each. Dose three is then compared to the active control with a non-inferiority
margin of 1.5 at the α = 0.025 level of significance. We find dose three to be sig-
nificantly non-inferior to the active control (p < 0.0001). This means this trial was
successful, as dose three was found both significantly better than placebo, and
33
non-inferior to the active control.
2.8.5 Hochberg Stage One, Bonferroni Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0.025
3
= 0.00833, at 95% power, yielding n=364 for each arm in the first stage. Using
the Bonferroni-adjusted 1-sided alpha of 0.025
3
= 0.00833, 90% power, and a non-
inferiority margin of 1.5, the necessary sample size for the second stage is n=1203
per group.
After data simulation, the first step of testing is to run the assay sensitivity test
on the active control and placebo groups with n=364 in each group. This involves
a t-test comparison, ensuring that the active control is significantly better than the
placebo (p = 0.0015) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=364 subjects per group. Then, we adjust the p-values based on the Hochberg
method and compare the adjusted p-values to the full alpha level. We find that
dose one (p = 0.976) and dose two (p = 0.976) are not significantly different from
placebo at the α = 0.025 level. Dose three is found to be significantly better than
placebo (p = 0.0085) at the α = 0.025 level of significance.
Dose three moves forward to the second stage of testing, enrolling 839 more
subjects into both the dose three and the active control arms for a total of n=1203
in each. Dose three is then compared to the active control with a non-inferiority
margin of 1.5 at the α = 0.00833 level of significance, because only one dose of the
three tested in the first stage was found to be significant. We find dose three to be
significantly non-inferior to the active control (p < 0.0001). This means this trial
was successful, as dose three was found both significantly better than placebo, and
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non-inferior to the active control.
Table 2.5: Simulated Example P-Values
Active
Stage One Stage Two Control v. Dose 1 v. Dose 2 v. Dose 3 v.
Adjustment Adjustment Placebo Placebo Placebo Placebo
Unadjusted Unadjusted 0.0099 0.4714 0.3286 0.022
Bonferroni Unadjusted 0.0018 0.9768 0.6746 0.0022
Bonferroni Bonferroni 0.0018 0.9768 0.6746 0.0022
Hochberg Unadjusted 0.0015 0.976 0.976 0.0085
Hochberg Bonferroni 0.0015 0.976 0.976 0.0085
Continued Simulated Example P-Values
Dose 1 v. Dose 2 v. Dose 3 v.
Stage One Stage Two Active Active Active
Adjustment Adjustment Control Control Control
Unadjusted Unadjusted 0.9521 0.9817 <.0001
Bonferroni Unadjusted 0.9521 0.9817 <.0001
Bonferroni Bonferroni 0.9947 0.9987 <.0001
Hochberg Unadjusted 0.9521 0.9817 <.0001
Hochberg Bonferroni 0.9947 0.9987 <.0001
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CHAPTER 3
Variable Non-Inferiority Margins in Seamless Superiority/Non-Inferiority
Clinical Trials
3.1 INTRODUCTION
Usually, the non-inferiority margin is determined during the design stage of a non-
inferiority clinical trial. It may be informed by historical data, preliminary pilot
studies, or a synthesis of historical and trial data, and is usually based on the active
control vs. placebo effect size in these previous studies. Then in the analysis phase,
assay sensitivity is assessed to determine if the active control effect is as-expected.
However, there are not always applicable historical trials to draw from.
We propose calculating an appropriate non-inferiority margin based on the
stage one findings of a seamless superiority/non-inferiority clinical trial, includ-
ing data from the placebo control arm. This allows us to better target the question
of interest, and more effectively design the second stage of the experiment.
3.2 METHODS
3.2.1 Non-Inferiority Margin
According to the FDA Guidance documents, the non-inferiority margin is deter-
mined off of two values:
M1 : The entire assumed effect of the Active Control
M2 : The largest clinically relevant difference between
the Treatment and Active Control
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M1 is typically based off of previous trials of the active control compared to placebo,
as there is no way to assess the true effect of the active control arm without the
presence of a placebo arm. The resulting non-inferiority margin (M) cannot be
larger than M1, the entire presumed effect of the active control. The validity of
the non-inferiority trial strongly depends on the choice of margin. If a too-large
M is chosen, such as one equal to or larger than the full effect of the active con-
trol vs. placebo, then a study may demonstrate non-inferiority of the experimental
treatment vs. an active control where no true experimental treatment effect exists.
Thus, a smaller margin, M2, is chosen for the study. M2 can be expressed as a
function of M1 : M2 = rM1 where 0<r<1, and is the preserved fraction of the full
treatment effect, driven by clinical reasoning. Showing non-inferiority with M2,
in addition to assay sensitivity, provides evidence that the experimental treatment
is non-inferior to the active control. However, it is important to retain clinical, as
well as statistical, effectiveness in the study. M2 must be smaller thanM1, and is the
largest clinically acceptable loss of effect of the active control that the experimental
treatment could have and still be useful.
Using past trials, the lower bound of the confidence interval of the estimated
active control effect vs. placebo is typically used as M1, and M2 is then deter-
mined based on clinical reasoning. M2 is then used as the non-inferiority margin,
tested at a pre-specified α-level. If the non-inferiority null hypothesis is rejected
with the margin M2, then the study has successfully shown clinically relevant
non-inferiority. These margins are calculated as follows, where z1−α is the criti-
cal z-value from the standard normal distribution, SEP−AC is the standard error
of the difference between the placebo and active control groups, M1 is the entire
presumed effect of the active control, and r is a proportion driven by clinical rea-
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soning. We denote the margins below as M1lb and M2lb meaning M1 lower bound
and M2 lower bound (FDA (CDER), 2016).
M1 = x¯Placebo − x¯ActiveControl
M1lb = M1 − (z1−α)SEP−AC
M2lb = rM1lb
Another approach to calculating the non-inferiority margin, suggested by Chow
and Shao, incorporates the variability of Active Control - Treatment within the cur-
rent clinical trial for both M1 and M2 as follows:
M3 = M1 − (z1−α + zβ)SEC−T
M4 = rM3
Where SEC−T is the standard error of the difference between the active control
and experimental treatment, SEC−T ≈ SET−P ≈ SEC−T , and z = Φ−1 (Chow &
Shao, 2006).
Here, we propose to assess the FWER and power after determining assay sen-
sitivity, using a non-inferiority margin informed by the first stage results. We use
a simulation study to numerically calculate the error and power rates, and seek
to determine the optimal analytical strategy for this design. We consider multiple
non-inferiority margins and adjustment schemes in this process.
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3.3 SIMULATION STUDY
3.3.1 Parameters
We performed a simulation study to numerically calculate the family-wise error
rate of the study, as well as the power, under 9 data configurations, using 5 differ-
ent multiplicity adjustment paradigms. The family-wise error rate of the study is
the probability of finding a truly inferior to active control experimental treatment
dose to be the most significantly better than placebo dose, as well as significantly
non-inferior to the active control. It is defined as follows:
FWER = P
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Where x¯i is the sample mean of arm i, ni is the sample size of arm i, α1 is the
nominal alpha level for the superiority stage test, α2 is the nominal alpha level
for the non-inferiority stage test, Mi is the non-inferiority margin, ni is the sample
size of arm i, and s is the square root of the pooled sample variance, defined as:
s2 = [(n1−1)s1+(n2−1)s2]
n1+n2−2 , where n1, n2 are the sample sizes in each of the 2 arms being
compared, and s1, s2 are the respective sample variances.
The power of the study was calculated as the likelihood of finding a truly non-
inferior to active control experimental treatment dose to be the most significantly
better than placebo and to be non-inferior to active control.
The non-inferiority margin was calculated at the interim analysis stage. M1 is
calculated as M1 = x¯Active Control − x¯Placebo using sample data from stage one. M1lb,
M2lb, M2, M3, andM4 are calculated as described above with r=12 , a common choice
of r when determining a non-inferiority margin.
3.3.2 Data Generation
We generated 20,000 datasets for each configuration of scenario, multiplicity ad-
justment, and margin calculation, encompassing the possible combinations of true
superiority to placebo, true inferiority to placebo, true non-inferiority to active con-
trol, and true inferiority to active control over the three dose possibilities. Based
on the motivating study parameters, the placebo group had an effect of -5 mmHg,
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and the active control group had an effect of -15 mmHg. The non-inferiority mar-
gin was set at 5 mmHg, half the difference between the placebo and active control
group effects. Therefore, the experimental treatment dose effects were varied from
-5 mmHg, -10 mmHg, to -15 mmHg (See Table 3.1) In simulation scenarios C1-C4,
the data generation assumptions correspond with a variation of overall null hy-
potheses; that is, none of the doses are truly non-inferior to the active control. C1
corresponds to a null hypothesis for the superiority to placebo test, where all of
the doses are truly equal to placebo. C4 corresponds to a null hypothesis for the
non-inferiority to the active control test, all of the doses are superior to the placebo
but, for each dose, the mean difference versus active control from which the sim-
ulations are generated, has a mean equal to the active control effect minus the
non-inferiority margin. C2 and C3 have one or two dose means equal to placebo
means, and one or two doses where the difference in means versus active control
is equal to the non-inferiority margin boundary as in C4.
In C5-C9, the data generation assumptions correspond to variations of alterna-
tive hypotheses. C5-C7 have one dose truly non-inferior to the active control, and
have one to two doses equal to placebo or on the non-inferiority margin boundary
as in C4. C8 and C9 have two doses truly non-inferior to the active control; C8’s
third dose being equal to placebo, while C9’s third dose is on the non-inferiority
margin boundary. These various conditions allow us to cover the range of com-
binations of null and alternative hypotheses to see how the family-wise error and
power changes over the different possible true dose combinations.
The null hypothesis for superiority and for non-inferiority can not be simu-
lated simultaneously. A null hypothesis for superiority is simulated by setting the
dose equal to the placebo, while a null hypothesis for non-inferiority is simulated
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by setting the dose equal to the active control minus the non-inferiority margin.
Therefore, we include a range of conditions that simulate a null hypothesis, and a
range of conditions to simulate potential alternative hypothesis.
Table 3.1: Data Simulation Parameters: Mean Changes from Base-
line; Standard Deviation is 10 mmHg within each group
Active
Dose 1 Dose 2 Dose 3 Control Placebo
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
C1 -5 -5 -5 -15 -5
C2 -5 -5 -10 -15 -5
C3 -5 -10 -10 -15 -5
C4 -10 -10 -10 -15 -5
C5 -5 -5 -15 -15 -5
C6 -5 -10 -15 -15 -5
C7 -10 -10 -15 -15 -5
C8 -5 -15 -15 -15 -5
C9 -10 -15 -15 -15 -5
To more wholly assess the benefit of using stage one data to entirely inform the
non-inferiority margin, we also repeat the simulation study on two misspecified
analyses. We explore simulated datasets with both a larger and smaller true differ-
ence between placebo and active control. The data simulation parameters for the
larger true difference is described in table 3.2 and for smaller true differences is de-
scribed in table 3.3. The simulated conditions which correspond to null hypotheses
are above the line, while those corresponding to alternative hypotheses are below.
In the case with a smaller true effect size, C2-C4 are truly non-inferior under the
non-inferiority null hypothesis described in Section 3.3.4 under the assumption of
M0.
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Table 3.2: Data Simulation Parameters: Larger True Effect, Mean
Changes from Baseline; Standard Deviation is 10 mmHg within each
group
Active
Dose 1 Dose 2 Dose 3 Control Placebo
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
C1 0 0 0 -15 0
C2 0 0 -7.5 -15 0
C3 0 -7.5 -7.5 -15 0
C4 -7.5 -7.5 -7.5 -15 0
C5 0 0 -15 -15 0
C6 0 -7.5 -15 -15 0
C7 -7.5 -7.5 -15 -15 0
C8 0 -15 -15 -15 0
C9 -7.5 -15 -15 -15 0
Table 3.3: Data Simulation Parameters: Smaller True Effect, Mean
Changes from Baseline; Standard Deviation is 10 mmHg within each
group
Active
Dose 1 Dose 2 Dose 3 Control Placebo
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
C1 -10 -10 -10 -15 -10
C2 -10 -10 -12.5 -15 -10
C3 -10 -12.5 -12.5 -15 -10
C4 -12.5 -12.5 -12.5 -15 -10
C5 -10 -10 -15 -15 -10
C6 -10 -12.5 -15 -15 -10
C7 -12.5 -12.5 -15 -15 -10
C8 -10 -15 -15 -15 -10
C9 -12.5 -15 -15 -15 -10
The simulation study was conducted using SAS version 9.4 via macro-
language. Data was analyzed via PROC GLM and PROC MULTTEST for the supe-
riority testing, and non-inferiority testing was carried out by hand in a DATA step
in SAS.
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3.3.3 Powering
PROC POWER is used to calculate sample size for each type of adjustment. For
each type of adjustment we considered, three power calculations were performed:
a calculation of the power to show superiority of at least one dose of the experi-
mental treatment over placebo in the first (superiority) stage of testing, a calcula-
tion of the power to show the superiority of the active control to placebo to ensure
assay sensitivity, and for the second (non-inferiority) stage of testing after the in-
terim analysis to show non-inferiority of the chosen experimental dose to the active
control.
For the superiority stage of testing comparing experimental treatment doses to
placebo, the unadjusted analyses were powered at a one-sided alpha of 0.025, 95%
power, with a standard deviation of 10, and group means of -5 and -15, yielding
a necessary 27 subjects per group. We power the assay sensitivity comparison of
active control vs. placebo at a one-sided alpha of 0.025, 95% power, with a standard
deviation of 10, and group means of -5 and -15, yielding a necessary 27 subjects
per group. As we assess both superiority and assay sensitivity in the first stage
of the analysis, powering each analysis at 95% yields and overall power for that
stage of 90% (95% x 95% ≈ 90%). For adjusted analysis comparing experimental
treatment doses to placebo, we powered using a Bonferroni-corrected one-sided
alpha of 0.025
3
= 0.00833 (where 3 is the number of experimental dose arms), 95%
power, with a standard deviation of 10, and group means of -5 and -15, yielding a
necessary 35 subjects per group. To power the assay sensitivity comparison in the
adjusted analyses, we use a one-sided alpha of 0.025, 95% power, with a standard
deviation of 10, and group means of -5 and -15, yielding a necessary 27 subjects
per group. We use the full one-sided alpha level of 0.025 when powering the assay
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sensitivity portion of the adjusted analysis because superiority to placebo must be
ascertained significantly for both an experimental treatment dose and the active
control dose, and therefore we do not need to adjust for the addition of the assay
sensitivity test.
For the non-inferiority stage of testing, the unadjusted analyses were powered
at a one-sided alpha of 0.025, 90% power, with a standard deviation of 10, group
means of -15 and -15, and non-inferiority margins equal to M0, M2, M2lb, and M4,
where M0 is equal to
(−5)−(−15)
2
= 5, based on our initial assumptions of the differ-
ence between placebo and active control, and serves as a standard for comparison,
and M2, M2lb, and M4 are as defined above.
In the second stage adjusted analysis, the critical alpha level is determined by
the number of experimental treatment dose arms found to be significant in the
first stage. If all three doses are significant, the full 0.025 alpha is used for second
stage testing. If only two doses are significant, then 2
3
× 0.025 = 0.0167 alpha
level is used, and if only one dose is significant in stage one, and alpha level of
1
3
× 0.025 = 0.00833 is used for second stage testing. We used 90% power, with a
standard deviation of 10, and group means of -15 and -15, with a non-inferiority
margin equal toM0,M2,M2lb, andM4, whereM0 is equal to
(−5)−(−15)
2
= 5, based on
our initial assumptions of the difference between placebo and active control, and
serves as a standard for comparison, and M2, M2lb, and M4 are as defined above.
In both adjusted and unadjusted non-inferiority powering analyses, we im-
posed a sample size limit of a 10x increase from the sample size that would have
resulted from our original assumptions. This resulted in any unadjusted studies
with greater than 860 subjects per arm, and 1100 subjects per arm for adjusted
studies, being stopped prematurely. This was a decision driven by practical con-
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siderations: in a real world setting, a study which was planned and budgeted for
a certain number of subjects is unlikely to be able to pivot to become a study 10
times the size. Additionally, at times there were computational issues with unreal-
istically large mandated sample sizes, and we needed to cap it.
3.3.4 Analytical Process
We employed an assay sensitivity test in stage one, ensuring that the active con-
trol led to a significantly larger decrease in sbp compared to the placebo, with the
below hypotheses.
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
If we cannot show that the active control has an effect over the placebo, then show-
ing that a dose is non-inferior to the active control does not give any meaningful in-
formation about the effect of the experimental treatment dose, rendering the entire
study meaningless. To avoid incurring temporal, financial, and clinical burdens
for study participants and sponsors, we perform this test before moving forward
with analysis (Temple, 2008).
Once each simulated study was shown to have significant evidence that the
active control was better than the placebo at the one-sided α = 0.025 level, each
dose was compared with placebo individually. The hypotheses are below.
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Each study was then tested using one of the adjustment paradigms discussed be-
low. If one or more doses were found to be significantly better than placebo in
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decreasing sbp, then the most significant dose was moved forward to the second
stage of testing. Based on the difference between placebo and control, the non-
inferiority margins were established for the second stage of testing.
M0 =
(−5)−(−15)
2
= 5
M2 =
1
2
(x¯Placebo − x¯ActiveControl)
M2lb =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α)SEP−AC)
M4 =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α + zβ)SEC−T )
A sample size calculation was carried out as described above in section 3.3.3,
and this most significant dose was tested in a non-inferiority framework as com-
pared to the active control.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, 2, 2lb, 4)
At this point both type 1 error and power were calculated for the overall study.
Superiority 
Test
Assay 
Sensitivity 
Test
Dose One
Dose Two
Dose Three
Placebo
Active 
Control
Dose Three v. Placebo
Dose Two v. Placebo
Dose One v. Placebo
Active Control  v. 
Placebo
Calculate 
NI Margin, 
Power, Add 
Subjects
Randomize 
to 5 Arms
Stage One
Dose Three 
(WLOG)
Active 
Control
Non-
Inferiority 
Test
Stage Two
Figure 3.1: Study Process
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3.3.5 Adjustment Methodologies
We explored unadjusted analyses, Bonferroni adjusted analyses, and Hochberg
adjusted analyses. The goal was to find the best combination of adjustments which
would control the type 1 error of the study overall, while giving the highest power.
We used the following six adjustment schema:
• Unadjusted in stage one, Unadjusted in stage two
• Bonferroni adjusted in stage one, Unadjusted in stage two
• Bonferroni adjusted in stage one, Bonferroni adjusted in stage two
• Hochberg adjusted in stage one, Unadjusted in stage two
• Hochberg adjusted in stage one, Bonferroni adjusted in stage two
In the first stage and in the second stage, an unadjusted analysis means that we
did not perform any multiplicity adjustment to the analysis and tested at the full-
alpha level. In the first stage, a Hochberg analysis means we utilized the Hochberg
multiplicity adjustment methodology as described above. For the first stage, a Bon-
ferroni adjustment means that we utilized the Bonferroni multiplicity adjustment
methodology as described above. For the second stage, a Bonferroni adjustment
means that we tested at an alpha level depending on how many superiority hy-
potheses were rejected in the first stage, as described below.
3.4 RESULTS
3.4.1 Unadjusted Stage One, Unadjusted Stage Two
First we considered the completely unadjusted analysis of this trial. We begin with
an assay sensitivity test of the hypothesis
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H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three in the
first stage at α = 0.025:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows:
M0 =
(−5)−(−15)
2
= 5
M2 =
1
2
(x¯Placebo − x¯ActiveControl)
M2lb =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α)SEP−AC)
M4 =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α + zβ)SEC−T )
and tested the non-inferiority hypothesis at α = 0.025
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, 2, 2lb, 4)
In C1-C4, the conditions correspond with a variation of overall null hypotheses;
that is, none of the doses are truly non-inferior to the active control. Conditions 5-9
correspond with a variety of alternative hypotheses.
In Table 3.4, we see that the family-wise error rate is controlled in C1 regardless
of the choice of non-inferiority margin, which corresponds with the superiority
null hypothesis. In this case, there is virtually zero family-wise error.
The family-wise error rate is controlled across all choices of non-inferiority mar-
gins tested in C2 as well, but not in C3 or C4. We see that the overall error increases
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as more doses have a larger effect, even a still inferior to active control effect. As
more experimental dosesâA˘Z´ true effect is on the non-inferiority margin, more
simulations will move past the first stage of testing correctly being found to be sig-
nificantly better than placebo. Then, those doses are tested in a non-inferiority set-
ting against the active control. By design there will be a proportion of simulations
found significant by chance, as weâA˘Z´re essentially testing the non-inferiority null
hypothesis.
We see that the use of either M2lb or M4 as the non-inferiority margin strongly
controls the error across all simulation conditions. These approaches to incorpo-
rating variance into the non-inferiority margin calculations yield very conservative
margins. With these smaller non-inferiority margins, the sample size calculations
more often yielded sample sizes that exceeded our upper limit of 10x the sample
size based on the original assumptions. The exclusion of these studies from com-
pletion yielded a lower simulated power for both of these margins (see Section
3.7).
With analyses using M0 and M2 as the non-inferiority margin, the FWER is in-
flated in C3 and in C4, which correspond with the non-inferiority null hypothesis.
Using M2 as the non-inferiority margin leads to a slight increase in error over M0,
which is the true non-inferiority margin as calculated from our simulation assump-
tions. When all two or three doses have a true effect that is equal to the difference
of the effect of the active control and the non-inferiority margin, then the error is
inflated due to multiple testing. We conclude that a clinical trial with this design
does need some adjustment to account for the multiple testing.
The studies were all designed to be powered at approximately 80%, and we see
that the simulated power is about as expected when using M0 or M2 as the non-
50
inferiority margins, though analyses using M2 have a slightly lower power than
those using M0 . We see considerably lower than expected power when using M2lb
and M4 as the non-inferiority margins.
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3.4.2 Bonferroni Stage One, Unadjusted Stage Two
Here we considered an analysis with a Bonferroni correction in the superiority
stage, and an uncorrected analysis in the non-inferiority stage. First we conducted
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three in the
first stage at α = 0.00833:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows:
M0 =
(−5)−(−15)
2
= 5
M2 =
1
2
(x¯Placebo − x¯ActiveControl)
M2lb =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α)SEP−AC)
M4 =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α + zβ)SEC−T )
and tested the non-inferiority hypothesis at α = 0.025
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, 2, 2lb, 4)
We see in Table 3.5 that the FWER is very similar to the completely unadjusted
analysis. If these two stages were split into two separate trials, this methodology
would widely be applied in practice. The phase II trial with three doses would
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have a Bonferroni correction, and the phase III trial comparing only one dose to an
active control would be tested with no multiplicity adjustment. However, though
analyses using M2 as the non-inferiority margin had a lower FWER than those
using M0 , with either choice of margin we find that a Bonferroni correction in the
first stage of testing alone is not sufficient to strongly control the family-wise error
rate of the study overall.
We see that applying a Bonferroni correction to the first stage of testing in-
creases the overall power of the study under all of the conditions. The sample size
calculations indicate an expected power of approximately 80% overall, and with
the use of M0 or M2 as the non-inferiority margin, we see simulated power a bit
higher than expected. With a choice ofM2lb orM4 as the non-inferiority margin, we
see a decrease in power. This occurs because M2lb and M4 are quite conservative
compared to M0 and M2 , and yield much larger sample sizes. The simulations
with large sample sizes fail to meet our criteria of having a sample size of less than
or equal to 10x the sample size calculated based on the original assumption, and
then are stopped at the interim. This causes the simulated power to be lower than
expected (see Section 3.7).
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55
3.4.3 Bonferroni Stage One, Bonferroni Stage Two
Here we considered an analysis with a Bonferroni correction in the superiority
stage, and a Bonferroni corrected analysis in the non-inferiority stage. First we
conducted an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three in the
first stage at α = 0.00833:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows:
M0 =
(−5)−(−15)
2
= 5
M2 =
1
2
(x¯Placebo − x¯ActiveControl)
M2lb =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α)SEP−AC)
M4 =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α + zβ)SEC−T )
If all three of the experimental doses were found to be significantly better than
placebo, in the first stage then the non-inferiority hypothesis (below) was tested at
the full α = 0.025. If two out of the three doses were found to be significantly better
than placebo, the non-inferiority hypothesis was tested at α = (2
3
)0.025 = 0.016667.
If only one dose was found to be significantly better than placebo in the first stage,
then the non-inferiority hypothesis was tested at α = (1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥Mj
56
H1 : µDose S − µActive Control < Mj
j ∈ (0, 2, 2lb, 4)
This methodology is not effective in strongly controlling the FWER- we see in
Table 3.6 that the highest error of any condition in the trial is 2.79%, when using
a non-inferiority margin of M2 , higher than the nominal 2.5% alpha level, and an
increase from analyses using the fixed non-inferiority margin of M0, which had a
maximum simulated error rate of 2.32%. When using non-inferiority margins M2lb
or M4 the error rates are very low. We know that the Bonferroni adjustment is
a good method for controlling the inflation of type 1 error in multiplicity adjust-
ment situations; however here we find that with M2 that it fails to do so. As the
most conservative multiplicity adjustment we considered, this gives us evidence
against using a data-based non-inferiority margin in this way. We see that the
power is slightly decreased from the approaches leaving both stages or only the
second stage unadjusted.
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3.4.4 Hochberg Stage One, Unadjusted Stage Two
Here we considered an analysis with a Hochberg correction in the superiority
stage, and an uncorrected analysis in the non-inferiority stage. First we conducted
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. Each of the three following hypotheses were
analyzed separately:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Then the resulting p-values were adjusted based on HochbergâA˘Z´s methodology
(Hochberg & Benjamini, 1995) as follows:
p˜(i) =

p(m) for i = m
min(p˜(i+1), (m− i+ 1)p(i)) for i = m− 1, · · · , 1
and then tested at α = 0.025.
Based on the first stage hypothesis test results, we calculated non-inferiority
margins as follows:
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M0 =
(−5)−(−15)
2
= 5
M2 =
1
2
(x¯Placebo − x¯ActiveControl)
M2lb =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α)SEP−AC)
M4 =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α + zβ)SEC−T )
Then the non-inferiority hypothesis below was tested at α = 0.025.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, 2, 2lb, 4)
We see that this methodology fails to strongly control the family-wise error
rate using either M0 or M2 as the non-inferiority margin. Under conditions three
and four, the simulated error rate exceeds that of the nominal rate of 2.5%. Non-
inferiority margins of M2lb and M4 do successfully control the error under all con-
ditions, with very low error rates across the board. However, these more conser-
vative non-inferiority margins yield substantially lower simulated power than the
expectation of 80%.
If these two stages were split into two separate trials, this methodology would
widely be applied in practice. The phase II trial with three doses would have a
Hochberg correction, and the phase III trial comparing only one dose to an active
control would be tested with no multiplicity adjustment. However, when using
M0 or M2 as the non-inferiority margins, we find that a Hochberg correction in the
first stage of testing alone is not sufficient to strongly control the family-wise error
rate of the study overall.
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3.4.5 Hochberg Stage One, Bonferroni Stage Two
Here we considered an analysis with a Hochberg correction in the superiority
stage, and an uncorrected analysis in the non-inferiority stage. First we conducted
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at a full one-sided α level of 0.025. Each of the three following hypotheses were
analyzed separately:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Then the resulting p-values were adjusted based on HochbergâA˘Z´s methodology
(Hochberg & Benjamini, 1995) as follows:
p˜(i) =

p(m) for i = m
min(p˜(i+1), (m− i+ 1)p(i)) for i = m− 1, · · · , 1
and then tested at α = 0.025.
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows:
M0 =
(−5)−(−15)
2
= 5
M2 =
1
2
(x¯Placebo − x¯ActiveControl)
M2lb =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α)SEP−AC)
M4 =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α + zβ)SEC−T )
If all three of the experimental doses were found to be significantly better than
placebo, in the first stage then the non-inferiority hypothesis (below) was tested at
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the full α = 0.025. If two out of the three doses were found to be significantly better
than placebo, the non-inferiority hypothesis was tested at α = (2
3
)0.025 = 0.016667.
If only one dose was found to be significantly better than placebo in the first stage,
then the non-inferiority hypothesis was tested at α = (1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, 2, 2lb, 4)
We see that this methodology fails to strongly control the family-wise error rate
using eitherM0 orM2 as the non-inferiority margin. Under condition four, the sim-
ulated error rate exceeds that of the nominal rate of 2.5%. The use of M2lb or M4 as
the non-inferiority margin does successfully control the error under all conditions,
with very low error rates across the board. However, these more conservative
margins yield substantially lower simulated power than the expectation of 80%,
and the relatively less conservative non-inferiority margin choice of M2 also has a
lower than expected simulated power.
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Two
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3.5 RESULTS FROM MISSPECIFIED MARGIN ANALYSIS
3.5.1 True Effect Size Larger than Assumption
As a benefit of this approach is providing a non-inferiority margin where there are
no historical trials to base it off of, we explore a misspecified larger than assumed
effect size to see how the methodology performs. We simulated 20,000 trials with
a larger true effect size than the original analysis (see Table 3.2).
This allows us to see whether the error rates are controlled when the assump-
tions of effect sizes are incorrect.
First we conducted an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three hypothe-
ses in the first stage at either α = 0.025 for unadjusted analyses, α = 0.00833 for
Bonferroni adjusted analyses, or test the Hochberg adjusted p-values (see section
2.3.1.2) at α = 0.025:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows:
M0 =
(−5)−(−15)
2
= 5
M2 =
1
2
(x¯Placebo − x¯ActiveControl)
M2lb =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α)SEP−AC)
M4 =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α + zβ)SEC−T )
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We assess using M0 = 5, even though the true margin is equal to 7.5 to assess
misspecified analysis results. In second stage unadjusted analyses, the below non-
inferiority null hypothesis was tested at the full α = 0.025 level of significance.
For the second stage Bonferroni adjusted analysis the below non-inferiority null
hypothesis was tested as follows: if all three of the experimental doses were found
to be significantly better than placebo, in the first stage then the non-inferiority
null hypothesis (below) was tested at the full α = 0.025. If two out of the three
doses were found to be significantly better than placebo, the non-inferiority null
hypothesis was tested at α = (2
3
)0.025 = 0.016667. If only one dose was found to
be significantly better than placebo in the first stage, then the non-inferiority null
hypothesis was tested at α = (1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, 2, 2lb, 4)
We see that the use of non-inferiority margins M2lb or M4 leads to very low
family-wise error rates (see Figures 3.2 and 3.3). Unlike the simulated power in
the correctly specified analysis, in the case where the true margin is larger than
assumed, the analyses using these margins achieve better than expected simulated
power (see Figures 3.4 and 3.5).
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Figure 3.2: M2L FWER Figure 3.3: M4 FWER
Figure 3.4: M2L Power Figure 3.5: M4 Power
The use of M2 does not strongly control the family-wise error rates. However,
we see in Figure 3.7 that the error rates when using M2 show a promising trend.
Whereas the incorrectly specified fixed margin M0 (Figure 3.6) has overly conser-
vative error rate control, the trend of error rates under margin M2 comes closer to
the pattern we see in the correctly specified analysis. However, as this methodol-
ogy does not strongly control the FWER under the correctly specified assumptions,
there is more work to be done in margin choice. The power between analyses using
M0 and M2 are comparable.
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Figure 3.6: M0 FWER Figure 3.7: M2 FWER
Figure 3.8: M0 Power Figure 3.9: M2 Power
3.5.2 True Effect Size Smaller than Assumption
We next explore a misspecified smaller true effect size to see how the methodol-
ogy performs. We simulated 20,000 trials with a smaller true effect size than the
original analysis (see Table 3.3).
This allows us to see whether the error rates are controlled when the assump-
tions of effect sizes are incorrect.
First we conducted an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
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at at full one-sided α level of 0.025. We tested each of the following three hypothe-
ses in the first stage at either α = 0.025 for unadjusted analyses, α = 0.00833 for
Bonferroni adjusted analyses, or test the Hochberg adjusted p-values (see section
2.3.1.2) at α = 0.025:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows:
M0 =
(−5)−(−15)
2
= 5
M2 =
1
2
(x¯Placebo − x¯ActiveControl)
M2lb =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α)SEP−AC)
M4 =
1
2
(x¯Placebo − x¯ActiveControl − (z1−α + zβ)SEC−T )
We assess using M0 = 5, even though the true margin is equal to 2.5 to assess
misspecified analysis results. In second stage unadjusted analyses, the below non-
inferiority null hypothesis was tested at the full α = 0.025 level of significance.
For the second stage Bonferroni adjusted analysis the below non-inferiority null
hypothesis was tested as follows: if all three of the experimental doses were found
to be significantly better than placebo, in the first stage then the non-inferiority
null hypothesis (below) was tested at the full α = 0.025. If two out of the three
doses were found to be significantly better than placebo, the non-inferiority null
hypothesis was tested at α = (2
3
)0.025 = 0.016667. If only one dose was found to
be significantly better than placebo in the first stage, then the non-inferiority null
hypothesis was tested at α = (1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥Mj
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H1 : µDose S − µActive Control < Mj
j ∈ (0, 2, 2lb, 4)
As we changed the effect sizes in this analysis, while still retaining our original
true hypotheses, only C1 still corresponds to a null hypothesis. C2-C4, which in
the true analysis correspond to a range of null hypotheses as all of the experimental
treatment group effect sizes were truly inferior to the active control. When the true
effect size changed (from -5 and -10, to -10 and -12.5, respectively), the true effect
size of the experimental treatment groups of -12.5 was within the non-inferiority
margin of 5, and therefore did not represent a null hypothesis.
We see that there is a very low family-wise error rate across all margins in the
condition corresponding to the placebo null hypothesis (Table 3.9). We cannot
assess an equivalent scenario for non-inferiority. We see that there is lower than
expected power (see Figures 3.10, 3.11, 3.12, and 3.13), as when the true margin is
smaller than the assumed margin, the analyses are underpowered.
Table 3.9: True Margin Smaller than Assumption Error Rates (C1)
Stage One Stage Two M0 M2 M2L M4
Adjustment Adjustment Error Error Error Error
Unadjusted Unadjusted 0.365 0.06 0 0
Bonferroni Unadjusted 0.355 0.04 0 0
Bonferroni Bonferroni 0.13 0.01 0 0
Hochberg Unadjusted 0.37 0.04 0 0
Hochberg Bonferroni 0.055 0.01 0 0
70
Figure 3.10: M0 Power Figure 3.11: M2 Power
Figure 3.12: M2L Power Figure 3.13: M4 Power
3.6 DISCUSSION
We have chosen three possible methods for calculation of non-fixed non-inferiority
margin to explore in this chapter, as well as one fixed non-inferiority margin calcu-
lation method to serve as a standard for comparison. We find that analyses using
M2lb or M4 as the non-inferiority margin strongly control the family-wise error rate
even without adjustment. However, these non-inferiority margins result in error
rates that are very conservative, and far smaller than the nominal level of 2.5%.
The simulated power under these non-inferiority margins is also much lower than
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the expected power of 80%. Using these margins in practice would likely yield un-
derpowered analyses or require a considerably larger sample size compared to the
expected sample size as per a priori assumptions. This makes M2lb and M4 poor
non-inferiority margin choices for practical use, even though they both strongly
control the family-wise error rate.
We find that the choice of M2 as the non-inferiority margin does not strongly
control the family-wise error rate, under any multiplicity adjustment scheme that
we assessed. It has positive power characteristics, maintaining close to the ex-
pected 80% power. However, we see in the misspecified analyses (Sections 3.5.2
and 3.5.1) that analyses using a fixed, incorrect non-inferiority margin of M0 do
not do as well as those using M2 as the non-inferiority margin. In the case with a
bigger than assumed true effect, the use of M2 as the non-inferiority margin makes
better use of the alpha available. In the case with a smaller than assumed true
effect, the use of M2 as the non-inferiority margin comes results in a lower error
rate. This suggests that there is some benefit to using stage one data to inform the
second stage design and analysis choices. However, none of the methods assessed
succeeded in strongly controlling the error at the nominal alpha level.
3.7 EXAMPLE OF SIMULATION PROCESS FOR CALCULATION OF SIMU-
LATED POWER
In this section, we illustrate how final simulated power is calculated. We use con-
dition 5 with no multiplicity adjustments in either stage with a non-inferiority mar-
gin of M2 to demonstrate this process.
In Figure 3.1 we see the entire study design process. Each of the 20,000 simu-
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lated datasets is run through this process. After the assay sensitivity test, 863 stud-
ies failed to show assay sensitivity (4.315%). This leaves 19,137 studies to enter the
superiority testing of stage one. Of these 19,137 studies, dose two was found to
be the most significantly better than placebo dose in 1 study (.005% of the original
20,000 studies). 819 studies were found to have no significant dose as compared
to placebo (4.095% of the original 20,000 studies). The remaining 18,317 studies
found dose three to be the most significantly better than placebo dose (91.585%
of the original 20,000 studies). In stage two, 16,356 simulations find dose 3 to be
significantly non-inferior to the active control. This corresponds to the simulated
power we calculated of 81.78%, as seen in Table 3.4.
3.8 SIMULATED CLINICAL TRIAL ILLUSTRATIVE EXAMPLE
In this section, we use one simulation of this clinical trial to illustrate our process.
We begin with simulating the data under condition five, using M2 as the non-
inferiority margin. Dose one, dose two, and the placebo arms have a mean effect
of -5, dose three and the active control arms have a mean effect of -15. All arms of
the trial have a standard deviation of 10.
3.8.1 Unadjusted Stage One, Unadjusted Stage Two
The sample size calculations are based on an unadjusted full 1-sided alpha of 0.025,
at 95% power, yielding n=27 for each arm in the first stage. After data simulation,
the first step of testing is to run the assay sensitivity test on the active control and
placebo groups with n=27 in each group. This involves a t-test comparison, ensur-
ing that the active control is significantly better than the placebo (p = 0.0002) at the
α = 0.025 level of significance.
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Once the study passed this step, we move on to the first stage of testing, with
n=27 subjects per group. We find that dose one (p = 0.6007) and dose two (p =
0.5054) are not significantly different from placebo at the α = 0.025 level. Dose
three is found to be significantly better than placebo (p < .0001) at the α = 0.025
level of significance.
The non-inferiority margin is then calculated (M2 ) using stage one results,
specifically dose three and active control means. This non-inferiority margin
(4.8994) is then used in a sample size calculation with 90% power, an unadjusted
full 1-sided alpha of 0.025, and assumed effect sizes of -15. Dose three moves
forward to the second stage of testing, enrolling 62 more subjects each into the
dose three and active control arms for a total of n=89 in each arm. Dose three is
then compared to the active control with a non-inferiority margin of 4.8994 at the
α = 0.025 level of significance. We find dose three to be significantly non-inferior
to the active control (p = 0.00020). This means this trial was successful, as dose
three was found both significantly better than placebo, and non-inferior to the ac-
tive control.
3.8.2 Bonferroni Stage One, Unadjusted Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0,025
3
= 0.00833, at 95% power, yielding n=35 for each arm in the first stage. After
data simulation, the first step of testing is to run the assay sensitivity test on the
active control and placebo groups with n=35 in each group. This involves a t-test
comparison, ensuring that the active control is significantly better than the placebo
(p = 0.0001) at the α = 0.025 level of significance.
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Once the study passed this step, we move on to the first stage of testing, with
n=35 subjects per group. We find that dose one (p = 0.7088) and dose two (p =
0.7042) are not significantly different from placebo at the α = 0.00833 level. Dose
three is found to be significantly better than placebo (p < .0001) at the α = 0.00833
level of significance.
The non-inferiority margin is then calculated (M2 ) using stage one results,
specifically dose three and active control means. This non-inferiority margin
(4.7029) is then used in a sample size calculation with 90% power, an unadjusted
full 1-sided alpha of 0.025, and assumed effect sizes of -15. Dose three moves for-
ward to the second stage of testing, enrolling 61 more subjects into both the dose
three and the active control arms for a total of n=96 in each. Dose three is then com-
pared to the active control with a non-inferiority margin of 4.7029 at the α = 0.025
level of significance. We find dose three to be significantly non-inferior to the ac-
tive control (p = 0.00020). This means this trial was successful, as dose three was
found both significantly better than placebo, and non-inferior to the active control.
3.8.3 Bonferroni Stage One, Bonferroni Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0.025
3
= 0.00833, at 95% power, yielding n=35 for each arm in the first stage. After
data simulation, the first step of testing is to run the assay sensitivity test on the
active control and placebo groups with n=35 in each group. This involves a t-test
comparison, ensuring that the active control is significantly better than the placebo
(p = 0.0001) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=35 subjects per group. We find that dose one (p = 0.7088) and dose two (p =
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0.7042) are not significantly different from placebo at the α = 0.00833 level. Dose
three is found to be significantly better than placebo (p < .0001) at the α = 0.00833
level of significance.
The non-inferiority margin is then calculated (M2 ) using stage one results,
specifically dose three and active control means. This non-inferiority margin
(4.7029) is then used in a sample size calculation with 90% power, a Bonferroni-
adjusted alpha of α = 0.00833, because only one experimental treatment dose out
of the three assessed in the first stage was found to be significant, and assumed
effect sizes of -15. Dose three moves forward to the second stage of testing, en-
rolling 89 more subjects into both the dose three and the active control arms for
a total of n=124 in each. Dose three is then compared to the active control with a
non-inferiority margin of 4.7029 at the α = 0.00833 level of significance. We find
dose three to be significantly non-inferior to the active control (p = 0.00005). This
means this trial was successful, as dose three was found both significantly better
than placebo, and non-inferior to the active control.
3.8.4 Hochberg Stage One, Unadjusted Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0.025
3
= 0.00833, at 95% power, yielding n=35 for each arm in the first stage. After
data simulation, the first step of testing is to run the assay sensitivity test on the
active control and placebo groups with n=35 in each group. This involves a t-test
comparison, ensuring that the active control is significantly better than the placebo
(p = 0.0002) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=35 subjects per group. Then, we adjust the p-values based on the Hochberg
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method and compare the adjusted p-values to the full alpha level. We find that
dose one (p = 0.7213) and dose two (p = 0.7213) are not significantly different from
placebo at the α = 0.025 level. Dose three is found to be significantly better than
placebo (p = 0.0011) at the α = 0.025 level of significance.
The non-inferiority margin is then calculated (M2 ) using stage one results,
specifically dose three and active control means. This non-inferiority margin
(4.7029) is then used in a sample size calculation with 90% power, an unadjusted
full 1-sided alpha of 0.025, and assumed effect sizes of -15. Dose three moves for-
ward to the second stage of testing, enrolling 61 more subjects into both the dose
three and the active control arms for a total of n=96 in each. Dose three is then com-
pared to the active control with a non-inferiority margin of 4.7029 at the α = 0.025
level of significance. We find dose three to be significantly non-inferior to the ac-
tive control (p = 0.00020). This means this trial was successful, as dose three was
found both significantly better than placebo, and non-inferior to the active control.
3.8.5 Hochberg Stage One, Bonferroni Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0.025
3
= 0.00833, at 95% power, yielding n=35 for each arm in the first stage. After
data simulation, the first step of testing is to run the assay sensitivity test on the
active control and placebo groups with n=35 in each group. This involves a t-test
comparison, ensuring that the active control is significantly better than the placebo
(p = 0.0002) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=35 subjects per group. Then, we adjust the p-values based on the Hochberg
method and compare the adjusted p-values to the full alpha level. We find that
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dose one (p = 0.7213) and dose two (p = 0.7213) are not significantly different from
placebo at the α = 0.025 level. Dose three is found to be significantly better than
placebo (p = 0.0011) at the α = 0.025 level of significance.
The non-inferiority margin is then calculated (M2 ) using stage one results,
specifically dose three and active control means. This non-inferiority margin
(4.7029) is then used in a sample size calculation with 90% power, a Bonferroni-
adjusted alpha of α = 0.00833, because only one experimental treatment dose out
of the three assessed in the first stage was found to be significant, and assumed
effect sizes of -15. Dose three moves forward to the second stage of testing, en-
rolling 89 more subjects into both the dose three and the active control arms for
a total of n=124 in each. Dose three is then compared to the active control with a
non-inferiority margin of 4.7029 at the α = 0.00833 level of significance. We find
dose three to be significantly non-inferior to the active control (p = 0.00005). This
means this trial was successful, as dose three was found both significantly better
than placebo, and non-inferior to the active control.
Table 3.10: Simulated Example P-Values
Active
Stage One Stage Two Control v. Dose 1 v. Dose 2 v. Dose 3 v.
Adjustment Adjustment Placebo Placebo Placebo Placebo
Unadjusted Unadjusted 0.0002 0.6007 0.5054 <.0001
Bonferroni Unadjusted 0.0001 0.7088 0.7042 <.0001
Bonferroni Bonferroni 0.0001 0.7088 0.7042 <.0001
Hochberg Unadjusted 0.0002 0.7213 0.7213 0.0011
Hochberg Bonferroni 0.0002 0.7213 0.7213 0.0011
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Continued Simulated Example P-Values
Dose 1 v. Dose 2 v. Dose 3 v.
Stage One Stage Two Active Active Active
Adjustment Adjustment Control Control Control
Unadjusted Unadjusted 0.99999 0.99991 0.00020
Bonferroni Unadjusted 0.99999 0.99996 0.00020
Bonferroni Bonferroni 1.00000 1.00000 0.00005
Hochberg Unadjusted 0.99999 0.99996 0.00020
Hochberg Bonferroni 1.00000 1.00000 0.00005
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CHAPTER 4
Synthesized Fixed and Variable Non-Inferiority Margins in Seamless
Superiority/Non-Inferiority Clinical Trials
4.1 INTRODUCTION
In Chapter 3 we assessed three variable non-inferiority margins, comparing a trial
design using one of those margins to the design using a fixed non-inferiority mar-
gin in Chapter 2. We found that a study using a non-inferiority margin based com-
pletely on stage one effect size results led to inflated family-wise error rates, even
after applying multiplicity control methodology. However, a fixed margin analy-
sis can lead to inflated error rates or an underpowered analysis if it is incorrectly
specified.
We propose calculating an appropriate synthesized non-inferiority margin
combining the a priori hypothesis based fixed non-inferiority margin and the
variable non-inferiority margin based on the stage one findings of a seamless
superiority/non-inferiority clinical trial, including data from the placebo control
arm. This allows us to better target the question of interest, while controlling the
family-wise error rates, and more effectively design the second stage of the exper-
iment.
4.2 METHODS
4.2.1 Tuning Parameter
The choice of a non-inferiority margin in a trial is a decision that must be driven
by clinical reasoning, as well as statistical foundations. Our synthesized margin is
defined, in part, by the tuning parameter, γ. This both gives more flexibility in the
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design of the trial, and adds a layer of complexity. Just as the preserved fraction
of the full treatment effect (Section 3.2.1) is a clinically driven decision, with some
statistical input as well, so is the choice of tuning parameter.
There are many factors to consider when making a choice of a γ. As it is a
mixing parameter between the fixed and variable margins, the choice is how to
proportionally weight the two ideas. If there is a strong basis for the a priori as-
sumed fixed margin, it makes sense to weigh it more heavily (and choose a rela-
tively larger γ, to weigh M0 higher). If there is less data supporting the original
assumption, the choice of a relatively smaller γ weighs the within-trial informed
variable margin higher.
An intuitive approach is to determine the γ based on sample sizes. If the fixed
margin is informed by a synthesis of historical trials with, for example, 10,000 sub-
jects total, while the current trial will enroll 1,000 subjects in the first stage, choos-
ing a tuning parameter which will weigh M0 more highly makes sense. However,
if M0 is formulated on the basis of trials with a total of 1,000 subjects, and the
new trial will have 1,000 subjects in it, choosing a tuning parameter which will
weigh the fixed and variable margins more evenly may be appropriate. In the
end, while these decisions must have statistically valid underpinnings, they are
clinically driven ones as well and should be made in a collaborative research envi-
ronment.
4.2.2 Synthesized Non-Inferiority Margin
The fixed non-inferiority margin approach is optimal if the a priori assumption
of the effect size is correct, controlling the FWER and sustaining adequate power
when appropriately adjusted for multiplicity. However, when the non-inferiority
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margin is assumed to be larger than the reality (Section 3.5.2), this approach fails to
control the error rates. When the non-inferiority margin is assumed to be smaller
than the reality (Section 3.5.1), the fixed-margin approach does not utilize all of the
available alpha and leads to quite conservative error rates.
The variable non-inferiority margin approach results in overly conservative er-
ror rates, when using non-inferiority margins M2lb and M4, or fail to control the
error rates when using non-inferiority margin Ms2. However, non-inferiority mar-
gin M2 shows a beneficial trend in the error rates when used as the non-inferiority
margin in a misspecified analysis. When the true effect size is larger than the as-
sumption (Section 3.5.1), the use of M2 as the non-inferiority margin leads to a
more promising trend of FWER (Figure 3.7), where the error is controlled when
correctly adjusted for multiplicity and takes advantage of more available alpha.
When the true effect size is smaller than the assumption (Section 3.5.2), the use
of M2 as the non-inferiority margin leads to lower FWER than the use of an in-
correctly specified M0 . The FWER in this case is controlled under correct multi-
plicity adjustment, and is lower than M0 under the other multiplicity adjustment
approaches.
As the fixed and variable margin approaches both have benefits and draw-
backs, we propose a synthesized margin of a weighted average between the fixed
and variable margins, defined below. The weighting is determined by a tuning
parameter, γ, and explored via simulations in this work.
M0 = 5
Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
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Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
4.3 SIMULATION STUDY
4.3.1 Parameters
We performed a simulation study to numerically calculate the family-wise error
rate of the study, as well as the power, under 9 data configurations, using 5 differ-
ent multiplicity adjustment paradigms. The family-wise error rate of the study is
the probability of finding a truly inferior to active control experimental treatment
dose to be the most significantly better than placebo dose, as well as significantly
non-inferior to the active control. It is defined as follows:
FWER = P

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
Where x¯i is the sample mean of arm i, ni is the sample size of arm i, α1 is the
nominal alpha level for the superiority stage test, α2 is the nominal alpha level
for the non-inferiority stage test, Mi is the non-inferiority margin, ni is the sample
size of arm i, and s is the square root of the pooled sample variance, defined as:
s2 = [(n1−1)s1+(n2−1)s2]
n1+n2−2 , where n1, n2 are the sample sizes in each of the 2 arms being
compared, and s1, s2 are the respective sample variances.
The power of the study was calculated as the likelihood of finding a truly non-
inferior to active control experimental treatment dose to be the most significantly
better than placebo and to be non-inferior to active control.
The fixed non-inferiority margin, M0, is defined by a priori assumptions. The
variable non-inferiority margins, M2, M2lb, and M4 were calculated at the interim
analysis stage, as described in Section 3.2.1. In this analysis, we look at a synthesis
of the fixed margin from Chapter 2 and the three variable margins from Chapter 3.
They are combined with a tuning parameter, γ, as described below.
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M0 = 5
Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
Ms2, Ms2lb, and Ms4 are calculated using sample data from stage one as de-
scribed in above with r = 1
2
, a common choice of r when determining a non-
inferiority margin in this therapeutic context.
4.3.2 Data Generation
We generated 20,000 datasets for each configuration of scenario, multiplicity ad-
justment, and margin calculation, exploring the full range of the tuning parameter,
γ. The simulations encompassed the possible combinations of true superiority to
placebo, true inferiority to placebo, true non-inferiority to active control, and true
inferiority to active control over the three dose possibilities. Based on the motivat-
ing study parameters, the placebo group had an effect of -5 mmHg, and the active
control group had an effect of -15 mmHg. The non-inferiority margin was set at
5 mmHg, half the difference between the placebo and active control group effects.
Therefore, the dose effects were varied from -5 mmHg, -10 mmHg, to -15 mmHg
(See Table 4.1) In simulation scenarios C1-C4, the data generation assumptions cor-
respond with a variation of overall null hypotheses; that is, none of the doses are
truly non-inferior to the active control. C1 corresponds to a null hypothesis for the
superiority to placebo test, where all of the doses are truly equal to placebo. C4 cor-
responds to a null hypothesis for the non-inferiority to the active control test, all of
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the doses are superior to the placebo but, for each dose, the mean difference versus
active control from which the simulations are generated, has a mean equal to the
active control effect minus the non-inferiority margin. C2 and C3 have one or two
dose means equal to placebo means, and one or two doses where the difference in
means versus active control is equal to the non-inferiority margin boundary as in
C4.
In C5-C9, the data generation assumptions correspond to variations of alterna-
tive hypotheses. C5-C7 have one dose truly non-inferior to the active control, and
have one to two doses equal to placebo or on the non-inferiority margin boundary
as in C4. C8 and C9 have two doses truly non-inferior to the active control; C8’s
third dose being equal to placebo, while C9’s third dose is on the non-inferiority
margin boundary. These various conditions allow us to cover the range of com-
binations of null and alternative hypotheses to see how the family-wise error and
power changes over the different possible true dose combinations.
The null hypothesis for superiority and for non-inferiority can not be simu-
lated simultaneously. A null hypothesis for superiority is simulated by setting the
dose equal to the placebo, while a null hypothesis for non-inferiority is simulated
by setting the dose equal to the active control minus the non-inferiority margin.
Therefore, we include a range of conditions that simulate a null hypothesis, and a
range of conditions to simulate potential alternative hypothesis.
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Table 4.1: Data Simulation Parameters: Effect Size
Active
Dose 1 Dose 2 Dose 3 Control Placebo
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
C1 -5 -5 -5 -15 -5
C2 -5 -5 -10 -15 -5
C3 -5 -10 -10 -15 -5
C4 -10 -10 -10 -15 -5
C5 -5 -5 -15 -15 -5
C6 -5 -10 -15 -15 -5
C7 -10 -10 -15 -15 -5
C8 -5 -15 -15 -15 -5
C9 -10 -15 -15 -15 -5
To more wholly assess the benefit of using stage one data to partially inform the
non-inferiority margin, we also run the entire simulation study on two misspeci-
fied analyses. We explore simulated datasets with both a larger and smaller true
difference between placebo and active control, as well as one where the placebo
and active treatment have a larger effect difference, but the null hypotheses are
still non-inferior according to our original study assumptions. The data simula-
tion parameters for this design are described in table 4.2, while the data simulation
parameters for the larger true effect difference are described in table 4.3 and for
smaller true effect differences are described in table 4.4. The simulated conditions
which correspond to null hypotheses are above the line, while those correspond-
ing to alternative hypotheses are below. In the case with a smaller true effect size,
C2-C4 are truly non-inferior under the non-inferiority null hypothesis described in
Section 4.3.4 under the assumption of M0.
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Table 4.2: Data Simulation Parameters: Alternate Placebo Effect
Size, Mean Changes from Baseline; Standard Deviation is 10 mmHg
within each group
Active
Dose 1 Dose 2 Dose 3 Control Placebo
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
C1 -3 -3 -3 -15 -3
C2 -3 -3 -10 -15 -3
C3 -3 -10 -10 -15 -3
C4 -10 -10 -10 -15 -3
C5 -3 -3 -15 -15 -3
C6 -3 -10 -15 -15 -3
C7 -10 -10 -15 -15 -3
C8 -3 -15 -15 -15 -3
C9 -10 -15 -15 -15 -3
Table 4.3: Data Simulation Parameters: Larger True Effect, Mean
Changes from Baseline; Standard Deviation is 10 mmHg within each
group
Active
Dose 1 Dose 2 Dose 3 Control Placebo
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
C1 0 0 0 -15 0
C2 0 0 -7.5 -15 0
C3 0 -7.5 -7.5 -15 0
C4 -7.5 -7.5 -7.5 -15 0
C5 0 0 -15 -15 0
C6 0 -7.5 -15 -15 0
C7 -7.5 -7.5 -15 -15 0
C8 0 -15 -15 -15 0
C9 -7.5 -15 -15 -15 0
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Table 4.4: Data Simulation Parameters: Smaller True Effect, Mean
Changes from Baseline; Standard Deviation is 10 mmHg within each
group
Active
Dose 1 Dose 2 Dose 3 Control Placebo
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
C1 -10 -10 -10 -15 -10
C2 -10 -10 -12.5 -15 -10
C3 -10 -12.5 -12.5 -15 -10
C4 -12.5 -12.5 -12.5 -15 -10
C5 -10 -10 -15 -15 -10
C6 -10 -12.5 -15 -15 -10
C7 -12.5 -12.5 -15 -15 -10
C8 -10 -15 -15 -15 -10
C9 -12.5 -15 -15 -15 -10
The simulation study was conducted using SAS version 9.4 via macro-
language. Data was analyzed via PROC GLM and PROC MULTTEST for the supe-
riority testing, and non-inferiority testing was carried out by hand in a DATA step
in SAS.
4.3.3 Powering
PROC POWER is used to calculate sample size for each type of adjustment. For
each type of adjustment we considered, three power calculations were performed:
a calculation of the power to show superiority of at least one dose of the experi-
mental treatment over placebo in the first (superiority) stage of testing, a calcula-
tion of the power to show the superiority of the active control to placebo to ensure
assay sensitivity, and for the second (non-inferiority) stage of testing after the in-
terim analysis to show non-inferiority of the chosen experimental dose to the active
control.
For the superiority stage of testing comparing experimental treatment doses to
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placebo, the unadjusted analyses were powered at a one-sided alpha of 0.025, 95%
power, with a standard deviation of 10, and group means of -5 and -15, yielding
a necessary 27 subjects per group. We power the assay sensitivity comparison of
active control vs. placebo at a one-sided alpha of 0.025, 95% power, with a standard
deviation of 10, and group means of -5 and -15, yielding a necessary 27 subjects
per group. As we assess both superiority and assay sensitivity in the first stage
of the analysis, powering each analysis at 95% yields and overall power for that
stage of 90% (95% x 95% ≈ 90%). For adjusted analysis comparing experimental
treatment doses to placebo, we powered using a Bonferroni-corrected one-sided
alpha of 0.025
3
= 0.00833 (where 3 is the number of experimental dose arms), 95%
power, with a standard deviation of 10, and group means of -5 and -15, yielding a
necessary 35 subjects per group. To power the assay sensitivity comparison in the
adjusted analyses, we use a one-sided alpha of 0.025, 95% power, with a standard
deviation of 10, and group means of -5 and -15, yielding a necessary 27 subjects
per group. We use the full one-sided alpha level of 0.025 when powering the assay
sensitivity portion of the adjusted analysis because superiority to placebo must be
ascertained significantly for both an experimental treatment dose and the active
control dose, and therefore we do not need to adjust for the addition of the assay
sensitivity test.
For the non-inferiority stage of testing, the unadjusted analyses were powered
at a one-sided alpha of 0.025, 90% power, with a standard deviation of 10, group
means of -15 and -15, and non-inferiority margins equal toM0, Ms2, Ms2lb, andMs4,
where M0 is equal to
(−5)−(−15)
2
= 5, based on our initial assumptions of the differ-
ence between placebo and active control, and serves as a standard for comparison,
and Ms2, Ms2lb, and Ms4 are as defined above. For adjusted analyses, we used a
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Bonferroni-corrected one-sided alpha of 0.00833, 90% power, with a standard de-
viation of 10, and group means of -15 and -15, with a non-inferiority margin equal
to M0, Ms2, Ms2lb, and Ms4, where M0 is equal to
(−5)−(−15)
2
= 5, based on our initial
assumptions of the difference between placebo and active control, and serves as a
standard for comparison, and Ms2, Ms2lb, and Ms4 are as defined above.
In the second stage adjusted analysis, the critical alpha level is determined by
the number of experimental treatment dose arms found to be significant in the
first stage. If all three doses are significant, the full 0.025 alpha is used for sec-
ond stage testing. If only two doses are significant, then 2
3
× 0.025 = 0.0167 alpha
level is used, and if only one dose is significant in stage one, and alpha level of
1
3
× 0.025 = 0.00833 is used for second stage testing. We used 90% power, with a
standard deviation of 10, and group means of -15 and -15, with a non-inferiority
margin equal toM0 , Ms2, Ms2lb, andMs4, whereM0 is equal to
(−5)−(−15)
2
= 5, based
on our initial assumptions of the difference between placebo and active control,
and serves as a standard for comparison, and Ms2, Ms2lb, and Ms4 are as defined
above. In both adjusted and unadjusted non-inferiority powering analyses, we im-
posed a sample size limit of a 10x increase from the sample size that would have
resulted from our original assumptions. This resulted in any unadjusted studies
with greater than 860 subjects per arm, and 1100 subjects per arm for adjusted
studies, being stopped prematurely. This was a decision driven by practical con-
siderations: in a real world setting, a study which was planned and budgeted for
a certain number of subjects is unlikely to be able to pivot to become a study 10
times the size. Additionally, at times there were computational issues with unreal-
istically large mandated sample sizes, and we needed to cap it.
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4.3.4 Analytical Process
We employed an assay sensitivity test in stage one, ensuring that the active con-
trol led to a significantly larger decrease in sbp compared to the placebo, with the
below hypotheses.
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
If we cannot show that the active control has an effect over the placebo, then show-
ing that a dose is non-inferior to the active control does not give any meaningful in-
formation about the effect of the experimental treatment dose, rendering the entire
study meaningless. To avoid incurring temporal, financial, and clinical burdens
for study participants and sponsors, we perform this test before moving forward
with analysis (Temple, 2008).
Once each simulated study was shown to have significant evidence that the
active control was better than the placebo at the one-sided α = 0.025 level, each
dose was compared with placebo individually. The hypotheses are below.
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Each study was then tested using one of the adjustment paradigms discussed be-
low. If one or more doses were found to be significantly better than placebo in
decreasing sbp, then the most significant dose was moved forward to the second
stage of testing. Based on the difference between placebo and control, the non-
inferiority margins were established for the second stage of testing.
M0 = 5
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Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
A sample size calculation was carried out as described above in section 4.3.3,
and this most significant dose was tested in a non-inferiority framework as com-
pared to the active control.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, s2, s2lb, s4)
At this point both family-wise error and power were calculated for the overall
study.
Superiority 
Test
Assay 
Sensitivity 
Test
Dose One
Dose Two
Dose Three
Placebo
Active 
Control
Dose Three v. Placebo
Dose Two v. Placebo
Dose One v. Placebo
Active Control  v. 
Placebo
Calculate 
Synthesized NI 
Margin, Power, 
Add Subjects
Randomize 
to 5 Arms
Stage One
Dose Three 
(WLOG)
Active 
Control
Non-
Inferiority 
Test
Stage Two
Figure 4.1: Study Process
4.3.5 Adjustment Methodologies
We explored unadjusted analyses, Bonferroni adjusted analyses, and Hochberg
adjusted analyses. The goal was to find the best combination of adjustments which
would control the type 1 error of the study overall, while giving the highest power.
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We used the following six adjustment schema:
• Unadjusted in stage one, Unadjusted in stage two
• Bonferroni adjusted in stage one, Unadjusted in stage two
• Bonferroni adjusted in stage one, Bonferroni adjusted in stage two
• Hochberg adjusted in stage one, Unadjusted in stage two
• Hochberg adjusted in stage one, Bonferroni adjusted in stage two
In the first stage and in the second stage, an unadjusted analysis means that we
did not perform any multiplicity adjustment to the analysis and tested at the full-
alpha level. In the first stage, a Hochberg analysis means we utilized the Hochberg
multiplicity adjustment methodology as described above. For the first stage, a Bon-
ferroni adjustment means that we utilized the Bonferroni multiplicity adjustment
methodology as described above. For the second stage, a Bonferroni adjustment
means that we tested at an alpha level depending on how many superiority hy-
potheses were rejected in the first stage, as described below.
4.4 RESULTS
4.4.1 Unadjusted Stage One, Unadjusted Stage Two
First we considered the completely unadjusted analysis of this trial. We begin with
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
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at at full one-sided α level of 0.025. We tested each of the following three in the
first stage at α = 0.025:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows, varying γ from 0 to 100:
M0 = 5
Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
and tested the non-inferiority hypothesis at α = 0.025
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, s2, s2lb, s4)
We find that the synthesized non-inferiority margins do a good job in control-
ling the family-wise error rate, even without a multiplicity adjustment, with the
correct choice of γ. In C1 (Figure 4.2) we see there is essentially no error across
all choices of non-inferiority margin, and tuning parameter. In C2 (Figure 4.3), the
fixed non-inferiority margin succeeds in controlling the error. Non-inferiority mar-
ginsMs2lb andMs4 have error trends less than or equal to the fixed margin,M0. Ms2
has a slightly higher error rate than M0 when γ is equal to 0, but is still controlled
at the nominal α level of 2.5%.
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Figure 4.2: C1 UU FWER Figure 4.3: C2 UU FWER
Under C3 (Figure 4.4), M0 fails to control the FWER at the nominal level. Ms2
succeeds in controlling the error when γ is between 0.10 and 0.95, inclusive. Ms2lb
and Ms4 both control the error when γ is less than 0.95. Under C4 (Figure 4.5), M0
again does not control the family-wise error rate, while Ms2 controls it when γ is
between 0.15 and 0.90. Ms2lb and Ms4 succeed in controlling the error rate when γ
is less than 0.90.
Figure 4.4: C3 UU FWER Figure 4.5: C4 UU FWER
Under C5 (Figure 4.6), the fixed margin, M0, maintains simulated power above
the expected level of 80%. The variable margin Ms2 maintains simulated power
above the expected 80% level across all values of γ. Ms2lb reaches expected simu-
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lated power when γ is 0.25 or greater, andMs4 does when γ is greater than or equal
to 0.35. Under C6 (Figure 4.7), M0 and Ms2 maintain simulated power above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.25 or greater, and Ms4 does
when γ is 0.40 or greater.
Figure 4.6: C5 UU Power Figure 4.7: C6 UU Power
Under C7 (Figure 4.8), the fixed margin, M0, maintains simulated power very
close to, but not reaching the expected level of 80%. The variable margin Ms2
maintains simulated power very close to, but not reaching the expected level of
80% across all values of γ. Ms2lb never reaches expected simulated power, however
when γ is 0.15 or greater, the simulated power is withing 10% of the expected
power, and when γ is 0.35 or greater Ms2lb is within 1% of the expected 80%. Ms4
gets within 15% of expected simulated power when γ is greater than or equal to
0.30, and gets within 1% of expected simulated power when γ is greater than or
equal to 0.50. Under C8 (Figure 4.9), M0 and Ms2 maintain simulated power above
80%. Ms2lb reaches simulated power over 80% when γ is 0.20 or greater, and Ms4
does when γ is 0.35 or greater.
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Figure 4.8: C7 UU Power Figure 4.9: C8 UU Power
Under C9 (Figure 4.10), M0 and Ms2 maintain simulated power above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.20 or greater, and Ms4 does
when γ is 0.35 or greater.
Figure 4.10: C9 UU Power
4.4.2 Bonferroni Stage One, Unadjusted Stage Two
Here we considered an analysis with a Bonferroni correction in the superiority
stage, and an uncorrected analysis in the non-inferiority stage. First we conducted
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
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at at full one-sided α level of 0.025. We tested each of the following three in the
first stage at α = 0.00833:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows, varying γ from 0 to 100:
M0 = 5
Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
and tested the non-inferiority hypothesis at α = 0.025
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, s2, s2lb, s4)
We find that the synthesized non-inferiority margins do a good job in control-
ling the family-wise error rate, even without a multiplicity adjustment, with the
correct choice of γ. In C1 (Figure 4.11) we see there is essentially no error across
all choices of non-inferiority margin, and tuning parameter. In C2 (Figure 4.12),
the fixed non-inferiority margin succeeds in controlling the error. Non-inferiority
margins Ms2lb and Ms4 have error trends less than or equal to the fixed margin,
M0. Ms2 has a slightly higher error rate than M0 when γ is equal to 0, but is still
controlled at the nominal α level of 2.5%.
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Figure 4.11: C1 BU FWER Figure 4.12: C2 BU FWER
Under C3 (Figure 4.13), M0 fails to control the FWER at the nominal level. Ms2
succeeds in controlling the error when γ is between 0.05 and 0.95, inclusive. Ms2lb
and Ms4 both control the error when γ is less than 0.95. Under C4 (Figure 4.14), M0
again does not control the family-wise error rate, while Ms2 controls it when γ is
between 0.1 and 0.90. Ms2lb and Ms4 succeed in controlling the error rate when γ is
less than 0.90.
Figure 4.13: C3 BU FWER Figure 4.14: C4 BU FWER
Under C5 (Figure 4.15), the fixed margin,M0, maintains simulated power above
the expected level of 80%. The variable margin Ms2 maintains simulated power
above the expected 80% level across all values of γ. Ms2lb reaches expected simu-
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lated power when γ is 0.15 or greater, andMs4 does when γ is greater than or equal
to 0.30. Under C6 (Figure 4.16), M0 and Ms2 maintain simulated power above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.15 or greater, and Ms4 does
when γ is 0.35 or greater.
Figure 4.15: C5 BU Power Figure 4.16: C6 BU Power
Under C7 (Figure 4.17), M0 and Ms2 maintain simulated power above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.20 or greater, and Ms4 does
when γ is 0.35 or greater. Under C8 (Figure 4.18), M0 and Ms2 maintain simulated
power well above 80%. Ms2lb reaches simulated power over 80% when γ is 0.10 or
greater, and Ms4 does when γ is 0.30 or greater.
Figure 4.17: C7 BU Power Figure 4.18: C8 BU Power
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Under C9 (Figure 4.28),M0 andMs2 maintain simulated power well above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.10 or greater, and Ms4 does
when γ is 0.30 or greater.
Figure 4.19: C9 BU Power
4.4.3 Bonferroni Stage One, Bonferroni Stage Two
Here we considered an analysis with a Bonferroni correction in the superiority
stage, and a Bonferroni corrected analysis in the non-inferiority stage. First we
conducted an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three in the
first stage at α = 0.00833:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows, varying γ from 0 to 100:
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M0 = 5
Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
If all three of the experimental doses were found to be significantly better than
placebo, in the first stage then the non-inferiority hypothesis (below) was tested at
the full α = 0.025. If two out of the three doses were found to be significantly better
than placebo, the non-inferiority hypothesis was tested at α = (2
3
)0.025 = 0.016667.
If only one dose was found to be significantly better than placebo in the first stage,
then the non-inferiority hypothesis was tested at α = (1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, s2, s2lb, s4)
We find that the synthesized non-inferiority margins do a good job in control-
ling the family-wise error rate, even without a multiplicity adjustment, with the
correct choice of γ. In C1 (Figure 4.20) we see there is essentially no error across
all choices of non-inferiority margin, and tuning parameter. In C2 (Figure 4.21),
the fixed non-inferiority margin succeeds in controlling the error. Non-inferiority
margins Ms2lb and Ms4 have error trends less than or equal to the fixed margin, M0.
Ms2 has a slightly higher error rate than M0 when γ is 0.05 or smaller, but is still
controlled at the nominal α level of 2.5%.
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Figure 4.20: C1 BB FWER Figure 4.21: C2 BB FWER
In C3 (Figure 4.22), the fixed non-inferiority margin, M0 , succeeds in control-
ling the error. Non-inferiority margins Ms2lb and Ms4 have error trends less than or
equal to the fixed margin, M0. Ms2 has a slightly higher error rate than M0 when
γ is 0.05 or less, but is still controlled at the nominal α level of 0.025. Under C4
(Figure 4.23), M0 again succeeds in controlling the family-wise error rate, while
Ms2 controls it when γ is greater than 0.05. Ms2lb and Ms4 succeed in controlling
the error rate across all values of γ.
Figure 4.22: C3 BB FWER Figure 4.23: C4 BB FWER
Under C5 (Figure 4.24), the fixed margin,M0, maintains simulated power above
the expected level of 80%. The variable margin Ms2 maintains simulated power
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above the expected 80% level across all values of γ. Ms2lb reaches expected simu-
lated power when γ is 0.15 or greater, andMs4 does when γ is greater than or equal
to 0.30. Under C6 (Figure 4.25), M0 and Ms2 maintain simulated power above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.15 or greater, and Ms4 does
when γ is 0.35 or greater.
Figure 4.24: C5 BB Power Figure 4.25: C6 BB Power
Under C7 (Figure 4.26), M0 and Ms2 maintain simulated power above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.20 or greater, and Ms4 does
when γ is 0.35 or greater. Under C8 (Figure 4.27), M0 and Ms2 maintain simulated
power well above 80%. Ms2lb reaches simulated power over 80% when γ is 0.10 or
greater, and Ms4 does when γ is 0.30 or greater.
Figure 4.26: C7 BB Power Figure 4.27: C8 BB Power
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Under C9 (Figure 4.28),M0 andMs2 maintain simulated power well above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.10 or greater, and Ms4 does
when γ is 0.30 or greater.
Figure 4.28: C9 BB Power
4.4.4 Hochberg Stage One, Unadjusted Stage Two
Here we considered an analysis with a Hochberg correction in the superiority
stage, and an uncorrected analysis in the non-inferiority stage. First we conducted
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. Each of the three following hypotheses were
analyzed separately:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Then the resulting p-values were adjusted based on Hochberg’s methodology
(Hochberg & Benjamini, 1995) as follows:
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p˜(i) =

p(m) for i = m
min(p˜(i+1), (m− i+ 1)p(i)) for i = m− 1, · · · , 1
and then tested at α = 0.025.
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows, varying γ from 0 to 100:
M0 = 5
Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
Then the non-inferiority hypothesis below was tested at α = 0.025.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, s2, s2lb, s4)
We find that the synthesized non-inferiority margins do a good job in control-
ling the family-wise error rate, even without a multiplicity adjustment, with the
correct choice of γ. In C1 (Figure 4.29) we see there is essentially no error across
all choices of non-inferiority margin, and tuning parameter. In C2 (Figure 4.30),
the fixed non-inferiority margin succeeds in controlling the error. Non-inferiority
margins Ms2lb and Ms4 have error trends less than or equal to the fixed margin, M0.
Ms2 has a slightly higher error rate than M0 when γ is 0.05 or smaller, but is still
controlled at the nominal α level of 2.5%.
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Figure 4.29: C1 HU FWER Figure 4.30: C2 HU FWER
In C3 (Figure 4.31), the fixed non-inferiority margin, M0, fails to control the
error at the nominal 2.5% α level. The variable non-inferiority margin Ms2 controls
the FWER when γ is between 0.05 and 0.95. Ms2lb and Ms4 have error trends less
than or equal to the fixed margin, M0, and control the error rate when γ is less than
0.95. Under C4 (Figure 4.32), M0 again fails to control the family-wise error rate,
while Ms2 controls it when γ is between 0.10 and 0.90. Ms2lb and Ms4 succeed in
controlling the error rate across all values of γ lower than 0.90.
Figure 4.31: C3 HU FWER Figure 4.32: C4 HU FWER
Under C5 (Figure 4.33), the fixed margin,M0, maintains simulated power above
the expected level of 80%. The variable margin Ms2 maintains simulated power
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above the expected 80% level across all values of γ. Ms2lb reaches expected simu-
lated power when γ is 0.15 or greater, andMs4 does when γ is greater than or equal
to 0.30. Under C6 (Figure 4.34), M0 and Ms2 maintain simulated power above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.20 or greater, and Ms4 does
when γ is 0.35 or greater.
Figure 4.33: C5 HU Power Figure 4.34: C6 HU Power
Under C7 (Figure 4.35), M0 and Ms2 maintain simulated power above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.20 or greater, and Ms4 does
when γ is 0.35 or greater. Under C8 (Figure 4.36), M0 and Ms2 maintain simulated
power well above 80%. Ms2lb reaches simulated power over 80% when γ is 0.10 or
greater, and Ms4 does when γ is 0.30 or greater.
Figure 4.35: C7 HU Power Figure 4.36: C8 HU Power
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Under C9 (Figure 4.37),M0 andMs2 maintain simulated power well above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.10 or greater, and Ms4 does
when γ is 0.30 or greater.
Figure 4.37: C9 HU Power
4.4.5 Hochberg Stage One, Bonferroni Stage Two
Here we considered an analysis with a Hochberg correction in the superiority
stage, and an uncorrected analysis in the non-inferiority stage. First we conducted
an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at a full one-sided α level of 0.025. Each of the three following hypotheses were
analyzed separately:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Then the resulting p-values were adjusted based on Hochberg’s methodology
(Hochberg & Benjamini, 1995) as follows:
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p˜(i) =

p(m) for i = m
min(p˜(i+1), (m− i+ 1)p(i)) for i = m− 1, · · · , 1
and then tested at α = 0.025.
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows, varying γ from 0 to 100:
M0 = 5
Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
Then if all three of the experimental doses were found to be significantly better
than placebo in the first stage, then the non-inferiority hypothesis (below) was
tested at the full α = 0.025. If two out of the three doses were found to be sig-
nificantly better than placebo, the non-inferiority hypothesis was tested at α =
(2
3
)0.025 = 0.016667. If only one dose was found to be significantly better than
placebo in the first stage, then the non-inferiority hypothesis was tested at α =
(1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, s2, s2lb, s4)
We find that the synthesized non-inferiority margins do a good job in control-
ling the family-wise error rate, even without a multiplicity adjustment, with the
correct choice of γ. In C1 (Figure 4.38) we see there is essentially no error across
all choices of non-inferiority margin, and tuning parameter. In C2 (Figure 4.39),
the fixed non-inferiority margin succeeds in controlling the error. Non-inferiority
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margins Ms2lb and Ms4 have error trends less than or equal to the fixed margin, M0.
Ms2 has a slightly higher error rate than M0 when γ is 0.05 or smaller, but is still
controlled at the nominal α level of 2.5%.
Figure 4.38: C1 HB FWER Figure 4.39: C2 HB FWER
In C3 (Figure 4.40), the fixed non-inferiority margin, M0, controls the error at
the nominal 2.5% α level. The variable non-inferiority marginMs2 leads to an error
rate higher than that of M0 when γ is 0.05 or less, but it still controls the FWER
across all values of the tuning parameter. Ms2lb and Ms4 have error trends less than
or equal to the fixed margin, M0. Under C4 (Figure 4.41), M0 again controls the
family-wise error rate, while Ms2 controls it when γ is greater than 0.05. Ms2lb and
Ms4 succeed in controlling the error rate across all values of γ.
Figure 4.40: C3 HB FWER Figure 4.41: C4 HB FWER
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Under C5 (Figure 4.42), the fixed margin,M0, maintains simulated power above
the expected level of 80%. The variable margin Ms2 maintains simulated power
above the expected 80% level across all values of γ. Ms2lb reaches expected simu-
lated power when γ is 0.25 or greater, andMs4 does when γ is greater than or equal
to 0.35. Under C6 (Figure 4.43), M0 and Ms2 maintain simulated power above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.25 or greater, and Ms4 does
when γ is 0.40 or greater.
Figure 4.42: C5 HB Power Figure 4.43: C6 HB Power
Under C7 (Figure 4.44),M0 maintains simulated power above 80%. Ms2 reaches
simulated power over 80% when γ is 0.20 or greater. Ms2lb reaches simulated power
over 80% when γ is 0.40 or greater, and Ms4 does when γ is 0.50 or greater. Under
C8 (Figure 4.45), M0 and Ms2 maintain simulated power well above 80%. Ms2lb
reaches simulated power over 80% when γ is 0.10 or greater, and Ms4 does when γ
is 0.30 or greater.
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Figure 4.44: C7 HB Power Figure 4.45: C8 HB Power
Under C9 (Figure 4.46),M0 andMs2 maintain simulated power well above 80%.
Ms2lb reaches simulated power over 80% when γ is 0.10 or greater, and Ms4 does
when γ is 0.30 or greater.
Figure 4.46: C9 HB Power
4.5 RESULTS FROM MISSPECIFIED MARGIN ANALYSIS
4.5.1 Misspecified Margin Due to an Alternate Placebo Effect Size
We explore a misspecified effect size to see how the methodology performs under
those circumstances. We simulated 20,000 trials with a misspecified effect size,
where the non-inferiority null hypothesis is still represented by C4, but the placebo
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effect size is less than our assumption, making the difference between placebo and
active control effect larger (see Table 4.2). This allows us to see whether the error
rates are controlled when the assumptions of effect sizes are incorrect.
First we conducted an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three hypothe-
ses in the first stage at either α = 0.025 for unadjusted analyses, α = 0.00833 for
Bonferroni adjusted analyses, or test the Hochberg adjusted p-values (see section
2.3.1.2) at α = 0.025:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows:
M0 = 5
Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
In second stage unadjusted analyses, the below non-inferiority null hypothesis
was tested at the full α = 0.025 level of significance. For the second stage Bon-
ferroni adjusted analysis the below non-inferiority null hypothesis was tested as
follows: if all three of the experimental doses were found to be significantly bet-
ter than placebo, in the first stage then the non-inferiority null hypothesis (below)
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was tested at the full α = 0.025. If two out of the three doses were found to be
significantly better than placebo, the non-inferiority null hypothesis was tested at
α = (2
3
)0.025 = 0.016667. If only one dose was found to be significantly better
than placebo in the first stage, then the non-inferiority null hypothesis was tested
at α = (1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, s2, s2lb, s4)
The simulation scenario C4 corresponds to the non-inferiority null hypothe-
sis, and results in the highest FWER. We explore scenario C4, as we have seen if
the error is controlled under C4, it is controlled under C1-C3 as well. We see that
though the experimental treatment dose effects in C4 in this analysis are equivalent
to those in C4 under the correctly specified analysis (Table 4.1), unlike in the cor-
rectly specified analysis, the fixed margin does not control the FWER even when
multiplicity adjustments are applied. This is due to the placebo effect compared
to active control being more extreme than in the correctly specified setting, and
therefore more experimental doses in stage one are found to be significant. Once
multiple doses are found to be significant, we take the experimental dose with the
largest effect size, which is systematically closer to the active control.
Under the Unadjusted/Unadjusted adjustment scheme, (Figure 4.47), M0 fails
to control the family-wise error rate. Ms2 controls the error when γ is between
0.40 and 0.80, inclusive. Ms2lb and Ms4 successfully control the FWER when γ is
0.85 or less. Under the Bonferroni/Unadjusted adjustment scheme, (Figure 4.48),
M0 again fails to control the family-wise error rate. Ms2 controls the error when γ
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is between 0.40 and 0.80, inclusive. Ms2lb and Ms4 successfully control the FWER
when γ is 0.85 or less.
Figure 4.47: C4 UU FWER Figure 4.48: C4 BU FWER
Under the Bonferroni/Bonferroni adjustment scheme, (Figure 4.49), M0 fails to
control the family-wise error rate. Ms2 controls the error when γ is between 0.35
and 0.80, inclusive. Ms2lb and Ms4 successfully control the FWER when γ is 0.90 or
less. Under the Hochberg/Unadjusted adjustment scheme, (Figure 4.50), M0 fails
to control the family-wise error rate. Ms2 controls the error when γ is between 0.40
and 0.80, inclusive. Ms2lb and Ms4 successfully control the FWER when γ is 0.85 or
less.
Figure 4.49: C4 BB FWER Figure 4.50: C4 HU FWER
117
Under the Hochberg/Bonferroni adjustment scheme, (Figure 4.51), M0 fails to
control the family-wise error rate. Ms2 controls the error when γ is between 0.40
and 0.85, inclusive. Ms2lb and Ms4 successfully control the FWER when γ is 0.90 or
less.
Figure 4.51: C4 HB FWER
The simulation scenario C7 corresponds to the alternative hypothesis which
results in the lowest simulated power. We explore scenario C7, as we have seen if
the simulated power is adequately high in C7, it is similarly adequate under C5,
C6, C8, and C9.
Under the Unadjusted/Unadjusted adjustment scheme (Figure 4.52), M0 and
Ms2 maintain simulated power above 80%. Ms2lb attains simulated power over
80% when γ is 0.15 or greater, while Ms4 reaches simulated power over 80% when
γ is 0.35 or greater. Under the Bonferroni/Unadjusted adjustment scheme (Figure
4.53), M0, Ms2, and Ms2lb maintain simulated power greater than the expected 80%
across all values of γ, while Ms4 reaches simulated power over 80% when γ is 0.25
or greater.
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Figure 4.52: C7 UU Power Figure 4.53: C7 BU Power
Under the Bonferroni/Bonferroni adjustment scheme (Figure 4.54), M0, Ms2,
and Ms2lb maintain simulated power greater than the expected 80% across all val-
ues of γ, while Ms4 reaches simulated power over 80% when γ is 0.25 or greater.
Under the Hochberg/Unadjusted adjustment scheme (Figure 4.55), M0, Ms2, and
Ms2lb maintain simulated power greater than the expected 80% across all values of
γ, while Ms4 reaches simulated power over 80% when γ is 0.25 or greater.
Figure 4.54: C7 BB Power Figure 4.55: C7 HU Power
Under the Hochberg/Bonferroni adjustment scheme (Figure 4.56), M0, Ms2,
and Ms2lb maintain simulated power greater than the expected 80% across all val-
ues of γ, while Ms4 reaches simulated power over 80% when γ is 0.25 or greater.
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Figure 4.56: C7 HB Power
4.5.2 True Effect Size Larger than Assumption
We explore a misspecified larger than assumed effect size to see how the methodol-
ogy performs under those circumstances. We simulated 20,000 trials with a larger
true effect size than the original analysis (see Table 4.3).
This allows us to see whether the error rates are controlled when the assump-
tions of effect sizes are incorrect.
First we conducted an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three hypothe-
ses in the first stage at either α = 0.025 for unadjusted analyses, α = 0.00833 for
Bonferroni adjusted analyses, or test the Hochberg adjusted p-values (see section
2.3.1.2) at α = 0.025:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
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Based on the first stage hypothesis test results, we calculated non-inferiority mar-
gins as follows:
M0 = 5
Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
We assess using M0 = 5, even though the true margin is equal to 7.5 to assess
misspecified analysis results. In second stage unadjusted analyses, the below non-
inferiority null hypothesis was tested at the full α = 0.025 level of significance.
For the second stage Bonferroni adjusted analysis the below non-inferiority null
hypothesis was tested as follows: if all three of the experimental doses were found
to be significantly better than placebo, in the first stage then the non-inferiority
null hypothesis (below) was tested at the full α = 0.025. If two out of the three
doses were found to be significantly better than placebo, the non-inferiority null
hypothesis was tested at α = (2
3
)0.025 = 0.016667. If only one dose was found to
be significantly better than placebo in the first stage, then the non-inferiority null
hypothesis was tested at α = (1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, s2, s2lb, s4)
The simulation scenario C4 corresponds to the non-inferiority null hypothesis,
and results in the highest FWER. We explore scenario C4, as we have seen if the
error is controlled under C4, it is controlled under C1-C3 as well.
Under the Unadjusted/Unadjusted adjustment scheme, (Figure 4.57), M0 con-
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trols the family-wise error rate, keeping it near zero, as do both Ms2lb and Ms4
across all values of γ. Ms2 controls it when γ is 0.05 or greater. Under the Bon-
ferroni/Unadjusted adjustment scheme, (Figure 4.58), M0 controls the family-wise
error rate, keeping it near zero, as do all three variable margins; Ms2, Ms2lb, and
Ms4 across all values of γ.
Figure 4.57: C4 UU FWER Figure 4.58: C4 BU FWER
Under the Bonferroni/Bonferroni adjustment scheme, (Figure 4.59), M0 con-
trols the family-wise error rate, keeping it near zero, as do all three variable mar-
gins; Ms2, Ms2lb, and Ms4 across all values of γ. Under the Hochberg/Unadjusted
adjustment scheme, (Figure 4.60), M0 controls the family-wise error rate, keeping
it near zero, as do all three variable margins; Ms2, Ms2lb, and Ms4 across all values
of γ.
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Figure 4.59: C4 BB FWER Figure 4.60: C4 HU FWER
Under the Hochberg/Bonferroni adjustment scheme, (Figure 4.61), M0 controls
the family-wise error rate, keeping it near zero, as do all three variable margins;
Ms2, Ms2lb, and Ms4 across all values of γ.
Figure 4.61: C4 HB FWER
The simulation scenario C7 corresponds to the alternative hypothesis which
results in the lowest simulated power. We explore scenario C7, as we have seen if
the simulated power is adequately high in C7, it is similarly adequate under C5,
C6, C8, and C9.
Under the Unadjusted/Unadjusted adjustment scheme (Figure 4.62), M0, Ms2,
and Ms2lb maintain simulated power above 80%. Ms4 reaches simulated power
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over 80% when γ is 0.15 or greater. Under the Bonferroni/Unadjusted adjustment
scheme (Figure 4.63), all margins maintain simulated power greater than the ex-
pected 80% across all values of γ.
Figure 4.62: C7 UU Power Figure 4.63: C7 BU Power
Under the Bonferroni/Bonferroni adjustment scheme (Figure 4.64), all margins
maintain simulated power greater than the expected 80%, across all values of γ.
Under the Hochberg/Unadjusted adjustment scheme (Figure 4.65), all margins
maintain simulated power greater than the expected 80%, across all values of γ.
Figure 4.64: C7 BB Power Figure 4.65: C7 HU Power
Under the Hochberg/Bonferroni adjustment scheme (Figure 4.66), all margins
maintain simulated power greater than the expected 80%, across all values of γ.
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Figure 4.66: C7 HB Power
4.5.3 True Effect Size Smaller than Assumption
We next explore a misspecified smaller true effect size to see how the methodol-
ogy performs. We simulated 20,000 trials with a smaller true effect size than the
original analysis (see Table 4.4). This allows us to see whether the error rates are
controlled when the assumptions of effect sizes are incorrect.
First we conducted an assay sensitivity test of the hypothesis
H0 : µActive Control ≤ µPlacebo
H1 : µActive Control > µPlacebo
at at full one-sided α level of 0.025. We tested each of the following three hypothe-
ses in the first stage at either α = 0.025 for unadjusted analyses, α = 0.00833 for
Bonferroni adjusted analyses, or test the Hochberg adjusted p-values (see section
2.3.1.2) at α = 0.025:
H0i : µDose i ≤ µPlacebo
H1i : µDose i > µPlacebo
i ∈ (1, 2, 3)
Based on the first stage hypothesis test results, we calculated non-inferiority mar-
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gins as follows:
M0 = 5
Ms2 = γ × (M0) + (1− γ)× (r(x¯Placebo − x¯ActiveControl))
Ms2lb = γ × (M0) + (1− γ)× (r(M1 − (z1−α)SEP−AC))
Ms4 = γ × (M0) + (1− γ)× (r(M1 − (z1−α + zβ)SEC−T ))
We assess using M0 = 5, even though the true margin is equal to 2.5 to assess
misspecified analysis results. In second stage unadjusted analyses, the below non-
inferiority null hypothesis was tested at the full α = 0.025 level of significance.
For the second stage Bonferroni adjusted analysis the below non-inferiority null
hypothesis was tested as follows: if all three of the experimental doses were found
to be significantly better than placebo, in the first stage then the non-inferiority
null hypothesis (below) was tested at the full α = 0.025. If two out of the three
doses were found to be significantly better than placebo, the non-inferiority null
hypothesis was tested at α = (2
3
)0.025 = 0.016667. If only one dose was found to
be significantly better than placebo in the first stage, then the non-inferiority null
hypothesis was tested at α = (1
3
)0.025 = 0.00833.
H0 : µDose S − µActive Control ≥Mj
H1 : µDose S − µActive Control < Mj
j ∈ (0, s2, s2lb, s4)
As we changed the effect sizes in this analysis, while still retaining our original
true hypotheses, only C1 still corresponds to a null hypothesis. C2-C4, which in
the true analysis correspond to a range of null hypotheses as all of the experimental
treatment group effect sizes were truly inferior to the active control. When the true
effect size changed (from -5 and -10, to -10 and -12.5, respectively), the true effect
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size of the experimental treatment groups of -12.5 was within the non-inferiority
margin of 5, and therefore did not represent a null hypothesis.
We see that there is a very low family-wise error rate across all margins in the
condition corresponding to the placebo null hypothesis (Figures 4.67, 4.68, 4.69,
4.70, and 4.71). Under all of the adjustment schemes, the FWER was controlled
both by the incorrect fixed margin, and the synthesized margins, across all val-
ues of the tuning parameter. We cannot assess an equivalent scenario for non-
inferiority.
Figure 4.67: C1 UU FWER Figure 4.68: C1 BU FWER
Figure 4.69: C1 BB FWER Figure 4.70: C1 HU FWER
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Figure 4.71: C1 HB FWER
We explore C2 and C9, as in this paradigm these two simulation conditions
yield the lowest and highest simulated power. We see that that there is much lower
than expected power, even in the best case scenario of C9. This holds true for the
Unadjusted/Unadjusted analysis, where for both C2 (Figure 4.72) and C9 (Figure
4.73) the simulated power did not reach the expected 80% with any combination
of margin choice and tuning parameter γ.
Figure 4.72: C2 UU Power Figure 4.73: C9 UU Power
In the Bonferroni/Unadjusted analysis, we see that that there is much lower
than expected power in both C2 (Figure 4.74) and C9 (Figure 4.75) where the simu-
lated power did not reach 80% with any combination of margin choice and tuning
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parameter γ.
Figure 4.74: C2 BU Power Figure 4.75: C9 BU Power
In the Bonferroni/Bonferroni analysis, we see that that there is much lower
than expected power in both C2 (Figure 4.76) and C9 (Figure 4.77) where the simu-
lated power did not reach 80% with any combination of margin choice and tuning
parameter γ.
Figure 4.76: C2 BB Power Figure 4.77: C9 BB Power
In the Hochberg/Unadjusted analysis, we see that that there is much lower
than expected power for both C2 (Figure 4.78) and C9 (Figure 4.79) where the sim-
ulated power did not reach 80% with any combination of margin choice and tuning
parameter γ.
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Figure 4.78: C2 HU Power Figure 4.79: C9 HU Power
In the Hochberg/Bonferroni analysis, we see that that there is much lower than
expected power for both C2 (Figure 4.80) and C9 (Figure 4.81) where the simu-
lated power did not reach 80% with any combination of margin choice and tuning
parameter γ.
Figure 4.80: C2 HB Power Figure 4.81: C9 HB Power
4.6 DISCUSSION
We have proposed and assessed three synthesized margins, combining the a priori
assumption of fixed effect size with the variable margin information coming from
the first stage of a trial. We compared each of these margins to the fixed margin
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explored fully in Chapter 2. We find that overall the synthesized margins suc-
cessfully control the family-wise error rate, and generally achieve expected simu-
lated power. These synthesized margins rely on an additional tuning parameter,
γ, which should be determined during the design planning stage of the study.
In the correctly specified analysis, the proposed margins Ms2lb and Ms4 control
the error under most values of γ across all 5 adjustment schemes. However, at
lower values of γ, the use of either of these non-inferiority margins results in very
low FWER. A synthesized margin of Ms2lb or Ms4 may be an attractive approach
as they both include an additional parameter for variance (Section 4.2.2), however
Ms2 has a more appealing balance of power and error rate properties. The non-
inferiority margin Ms2 successfully controls the FWER at the nominal α level of
2.5% under any of the adjustment methodologies proposed when γ is greater than
or equal to 0.05 and is less than or equal to 0.90. Under each of the adjustment
schemes, using Ms2 as the non-inferiority margin assures that power remains at or
above the expected level of 80%.
In the misspecified analyses with an alternate placebo effect size, we see that the
fixed margin fails to control the family-wise error rate, while the correct combina-
tions of synthesized margin choice, tuning parameter, and adjustment methodolo-
gies are successful. Under all adjustment schemes, analyses with non-inferiority
margin Ms2 successfully control the FWER when γ is between 0.40 and 0.80. With
Ms2, when there is no adjustment, any choice of γ 0.15 or greater leads to an ade-
quate power. With any other multiplicity adjustment scheme applied, Ms2 is ad-
equately powered across any choice of γ. In misspecified analyses when the true
margin is larger than assumed, the synthesized margins control the FWER across
almost all combinations of multiplicity adjustment, margin, and choice of tuning
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parameter. The only exception is in the Unadjusted/Unadjusted case, where when
γ is less than 0.05 the error rate is inflated past the nominal alpha level of 2.5%
when using Ms2. These analyses are all adequately powered as well, with the
only exception being in the Unadjusted/Unadjusted approach with Ms2lb, when
γ is less than 0.15. When the true margin is smaller than the assumption, FWER
is controlled across all assessed combinations of margin, multiplicity adjustment,
and γ choices. Power is found to be quite low, never rising close to the expected
level of 80%. This underscores the importance of having a good basis for your
non-inferiority margin assumptions. While FWER will be adequately controlled,
an incorrect choice may result in an underpowered study.
The choice of γ affects the weight that the a priori assumption is given com-
pared to the weight given to the first stage results in determining the synthesized
non-inferiority margin. In addition to the range of γ determined to adequately con-
trol the family-wise error rate, the choice of γ within that range should be consid-
ered carefully. We recommend basing this choice on the stability of the historically
based assumption of the a priori fixed margin. For example, if the fixed margin,
M0, is based on multiple historical clinical trials amounting to 5,000 subjects, while
the first stage of the new clinical trial includes about 200 subjects, a choice of a
higher γ would put more weight on the historical assumption. However, if M0 is
based off of about 200 subjects, and the new clinical trial adds an additional 200
subjects, it might make sense to choose a γ which would more evenly balance both
sets of information. These decisions are imperative in the design of a seamless
superiority/non-inferiority clinical trial, and have a direct baring on the adequate
control of the error. However, they must be made individually for each trial, tak-
ing into account clinical judgment as well as the statistical characteristics of this
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design.
4.7 EXAMPLE OF SIMULATION PROCESS FOR CALCULATION OF SIMU-
LATED POWER
In this section, we illustrate how final simulated power is calculated. We use con-
dition 5 with no multiplicity adjustments in either stage with a non-inferiority mar-
gin of Ms2 and a tuning parameter, γ, of 0.50 to demonstrate this process.
In Figure 4.1 we see the entire study design process. Each of the 20,000 simulated
datasets is run through this process. After the assay sensitivity test, 867 studies
failed to show assay sensitivity (4.335%). This leaves 19,133 studies to enter the
superiority testing of stage one. Of these 19,133 studies, dose one was found to be
the most significantly better than placebo dose in 3 studies (.015% of the original
20,000 studies) and dose two was found to be the most significantly better than
placebo dose in 1 study (.005% of the original 20,000 studies). 785 studies were
found to have no significant dose as compared to placebo (3.925% of the original
20,000 studies). The remaining 18,344 studies found dose three to be the most sig-
nificantly better than placebo dose (91.72% of the original 20,000 studies). In stage
two, 16,617 simulations find dose 3 to be significantly non-inferior to the active
control. This corresponds to the simulated power we calculated of 83.085%.
4.8 SIMULATED CLINICAL TRIAL ILLUSTRATIVE EXAMPLE
In this section, we use one simulation of this clinical trial to illustrate our process.
We begin with simulating the data under condition five, using Ms2 as the non-
inferiority margin, and a tuning parameter, γ, of 0.50. Dose one, dose two, and the
placebo arms have a mean effect of -5, dose three and the active control arms have
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a mean effect of -15. All arms of the trial have a standard deviation of 10.
4.8.1 Unadjusted Stage One, Unadjusted Stage Two
The sample size calculations are based on an unadjusted full 1-sided alpha of 0.025,
at 95% power, yielding n=27 for each arm in the first stage. After data simulation,
the first step of testing is to run the assay sensitivity test on the active control and
placebo groups with n=27 in each group. This involves a t-test comparison, ensur-
ing that the active control is significantly better than the placebo (p = 0.0024) at the
α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=27 subjects per group. We find that dose one (p = 0.3533) and dose two (p =
0.1036) are not significantly different from placebo at the α = 0.025 level. Dose
three is found to be significantly better than placebo (p = 0.0017) at the α = 0.025
level of significance.
The non-inferiority margin is then calculated (Ms2, with γ = 0.50) using stage
one results, specifically dose three and active control means. This non-inferiority
margin (4.20815) is then used in a sample size calculation with 90% power, an
unadjusted full 1-sided alpha of 0.025, and assumed effect sizes of -15. Dose three
moves forward to the second stage of testing, enrolling 93 more subjects each into
the dose three and active control arms for a total of n=120 in each arm. Dose three
is then compared to the active control with a non-inferiority margin of 4.20815 at
the α = 0.025 level of significance. We find dose three to be significantly non-
inferior to the active control (p = 0.00043). This means this trial was successful,
as dose three was found both significantly better than placebo, and non-inferior to
the active control.
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4.8.2 Bonferroni Stage One, Unadjusted Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0,025
3
= 0.00833, at 95% power, yielding n=35 for each arm in the first stage. After
data simulation, the first step of testing is to run the assay sensitivity test on the
active control and placebo groups with n=35 in each group. This involves a t-test
comparison, ensuring that the active control is significantly better than the placebo
(p = 0.0013) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=35 subjects per group. We find that dose one (p = 0.2150) and dose two (p =
0.0530) are not significantly different from placebo at the α = 0.00833 level. Dose
three is found to be significantly better than placebo (p = 0.0004) at the α = 0.00833
level of significance.
The non-inferiority margin is then calculated (Ms2, with γ = 0.50) using stage
one results, specifically dose three and active control means. This non-inferiority
margin (4.10995) is then used in a sample size calculation with 90% power, an
unadjusted full 1-sided alpha of 0.025, and assumed effect sizes of -15. Dose three
moves forward to the second stage of testing, enrolling 91 more subjects into both
the dose three and the active control arms for a total of n=126 in each. Dose three
is then compared to the active control with a non-inferiority margin of 4.10995 at
the α = 0.025 level of significance. We find dose three to be significantly non-
inferior to the active control (p = 0.00010). This means this trial was successful,
as dose three was found both significantly better than placebo, and non-inferior to
the active control.
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4.8.3 Bonferroni Stage One, Bonferroni Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0.025
3
= 0.00833, at 95% power, yielding n=35 for each arm in the first stage. After
data simulation, the first step of testing is to run the assay sensitivity test on the
active control and placebo groups with n=35 in each group. This involves a t-test
comparison, ensuring that the active control is significantly better than the placebo
(p = 0.0013) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=35 subjects per group. We find that dose one (p = 0.2150) and dose two (p =
0.0530) are not significantly different from placebo at the α = 0.00833 level. Dose
three is found to be significantly better than placebo (p = 0.0004) at the α = 0.00833
level of significance.
The non-inferiority margin is then calculated (Ms2, with γ = 0.50) using stage
one results, specifically dose three and active control means. This non-inferiority
margin (4.10995) is then used in a sample size calculation with 90% power, a
Bonferroni-adjusted alpha of α = 0.00833, because only one experimental treat-
ment dose out of the three assessed in the first stage was found to be significant,
and assumed effect sizes of -15. Dose three moves forward to the second stage of
testing, enrolling 127 more subjects into both the dose three and the active control
arms for a total of n=162 in each. Dose three is then compared to the active control
with a non-inferiority margin of 4.10995 at the α = 0.00833 level of significance. We
find dose three to be significantly non-inferior to the active control (p = 0.000004).
This means this trial was successful, as dose three was found both significantly
better than placebo, and non-inferior to the active control.
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4.8.4 Hochberg Stage One, Unadjusted Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0.025
3
= 0.00833, at 95% power, yielding n=35 for each arm in the first stage. After
data simulation, the first step of testing is to run the assay sensitivity test on the
active control and placebo groups with n=35 in each group. This involves a t-test
comparison, ensuring that the active control is significantly better than the placebo
(p = 0.0027) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=35 subjects per group. Then, we adjust the p-values based on the Hochberg
method and compare the adjusted p-values to the full alpha level. We find that
dose one (p = 0.2256) and dose two (p = 0.0875) are not significantly different from
placebo at the α = 0.025 level. Dose three is found to be significantly better than
placebo (p = 0.0038) at the α = 0.025 level of significance.
The non-inferiority margin is then calculated (Ms2, with γ = 0.50) using stage
one results, specifically dose three and active control means. This non-inferiority
margin (4.10995) is then used in a sample size calculation with 90% power, an
unadjusted full 1-sided alpha of 0.025, and assumed effect sizes of -15. Dose three
moves forward to the second stage of testing, enrolling 91 more subjects into both
the dose three and the active control arms for a total of n=126 in each. Dose three
is then compared to the active control with a non-inferiority margin of 4.10995 at
the α = 0.025 level of significance. We find dose three to be significantly non-
inferior to the active control (p = 0.00010). This means this trial was successful,
as dose three was found both significantly better than placebo, and non-inferior to
the active control.
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4.8.5 Hochberg Stage One, Bonferroni Stage Two
The sample size calculations are based on a Bonferroni-adjusted 1-sided alpha of
0.025
3
= 0.00833, at 95% power, yielding n=35 for each arm in the first stage. After
data simulation, the first step of testing is to run the assay sensitivity test on the
active control and placebo groups with n=35 in each group. This involves a t-test
comparison, ensuring that the active control is significantly better than the placebo
(p = 0.0027) at the α = 0.025 level of significance.
Once the study passed this step, we move on to the first stage of testing, with
n=35 subjects per group. Then, we adjust the p-values based on the Hochberg
method and compare the adjusted p-values to the full alpha level. We find that
dose one (p = 0.2256) and dose two (p = 0.0875) are not significantly different from
placebo at the α = 0.025 level. Dose three is found to be significantly better than
placebo (p = 0.0038) at the α = 0.025 level of significance.
The non-inferiority margin is then calculated (Ms2, with γ = 0.50) using stage
one results, specifically dose three and active control means. This non-inferiority
margin (4.10995) is then used in a sample size calculation with 90% power, a
Bonferroni-adjusted alpha of α = 0.00833, because only one experimental treat-
ment dose out of the three assessed in the first stage was found to be significant,
and assumed effect sizes of -15. Dose three moves forward to the second stage of
testing, enrolling 127 more subjects into both the dose three and the active control
arms for a total of n=162 in each. Dose three is then compared to the active control
with a non-inferiority margin of 4.10995 at the α = 0.00833 level of significance. We
find dose three to be significantly non-inferior to the active control (p = 0.000004).
This means this trial was successful, as dose three was found both significantly
better than placebo, and non-inferior to the active control.
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CHAPTER 5
Conclusion
We define a seamless superiority/non-inferiority clinical trial as one where the
first stage (the learning/phase II stage) is to find the most superior dose of an ex-
perimental treatment as compared to placebo, followed by the second stage (con-
firmatory/phase III) consisting of a non-inferiority assessment of the most supe-
rior dose to an active control. Seamless trial designs have the potential to impact
clinical drug development in myriads of ways. Depending on the specific trial, it
may take less time, necessitate less subjects, or glean information more efficiently.
However, before benefiting from these advances, it is imperative that we ensure
the design and analysis plan are adequately controlling the family-wise error rate
of the trial.
In Chapter Two, we determine the best analytical course for our seamless
superiority/non-inferiority trial. We show that though this trial design mandates
two significant endpoints for success, there is still a need for adjustment. The com-
pletely unadjusted analysis results in an increase in FWER over the nominal alpha-
level of 2.5%. We recommend using Hochberg corrected p-values when comparing
the three doses to placebo, and using a Bonferroni correction when assessing the
non-inferiority hypothesis. This approach controls the family-wise error rate, takes
the most advantage of the alpha available, without a loss of power.
In Chapter Three, we consider variable non-inferiority margins informed by the
first stage of the trial. The fixed margin from Chapter Two serves as a comparison
for three possible methods for calculation of non-fixed non-inferiority margin. We
find that analyses using non-inferiority marginsM2lb orM4 result in underpowered
analyses and are too conservative.
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We find that though the choice of M2 as the non-inferiority margin achieves
adequate power, it does not strongly control the family-wise error rate, regardless
of multiplicity adjustment scheme applied. However, we see in the misspecified
analyses that analyses using a fixed, incorrect non-inferiority margin of M0 do not
perform as well as those using M2 as the non-inferiority margin in regards to the
error curve characteristics. This suggests that there is some benefit to using stage
one data to inform the second stage design and analysis choices.
In Chapter Four, we define and assess new non-inferiority margin synthesiz-
ing the fixed a priori hypothesis non-inferiority margin with the variable non-
inferiority margins defined from within-study results. We find that overall the
synthesized margins successfully control the family-wise error rate, and generally
achieve expected simulated power. These synthesized margins rely on an addi-
tional tuning parameter, γ, which should be determined during the design plan-
ning stage of the study.
We conclude that Ms2 has the most appealing balance of power and error rate
properties. When the a priori assumption of the active control v. placebo control
effect size is correct, or smaller than the reality, the non-inferiority margin Ms2
successfully controls the FWER at the nominal α level of 2.5% under any of the
adjustment methodologies proposed when γ is greater than or equal to 0.40 and is
less than or equal to 0.80. Under each of the adjustment schemes, using Ms2 as the
non-inferiority margin with the same range of γ assures that power remains at or
above the expected level of 80%. However, when the true margin is smaller than
the assumed difference in effect size, power is found to be quite low, never rising
close to the expected level of 80%. This underscores the importance of having
a good basis for your non-inferiority margin assumptions. While FWER will be
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adequately controlled, an incorrect choice may result in an underpowered study.
The choice of γ affects the weight that the a priori assumption is given com-
pared to the weight given to the first stage results in determining the synthesized
non-inferiority margin. In addition to the range of γ determined to adequately con-
trol the family-wise error rate, the choice of γ within that range should be consid-
ered carefully. We recommend basing this choice on the stability of the historically
based assumption of the a priori fixed margin.
Parameter assumption choices in the design stage of a seamless superiority/non-
inferiority clinical trial are hugely impactful and have a direct baring on the ade-
quate control of the error. As the successful control of the family-wise error rate
along with achievement of adequate power, depends on correct specification of the
non-inferiority margin, adequate evidence to inform this assumption is imperative
in this design. However, they must be made individually for each trial, taking into
account clinical judgment as well as the statistical characteristics of this design.
We recommend using a synthesized non-inferiority margin, Ms2, with a Hochberg
multiplicity adjustment in the first stage followed by a Bonferroni adjustment for
the second stage, with a γ between 0.40 and 0.80. The exact choice of both a priori
fixed non-inferiority margin, M0, and tuning parameter should be made in concert
with the study team including biostatisticians and clinicians, along with appropri-
ate regulatory agencies.
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APPENDIX A
Appendix A: Tables
A.1 CHAPTER THREE ADDITIONAL TABLES
A.1.1 True Effect Size Bigger Than Assumption Error and Power Tables
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A.1.2 True Effect Size Smaller Than Assumption Error and Power Tables
M
ar
gi
n
=
M
0
=
5
M
ar
gi
n
=
M
2
M
ar
gi
n
=
M
2_
lb
M
ar
gi
n
=
M
4
Si
m
ul
at
io
n
C
on
di
ti
on
Er
ro
r
Po
w
er
A
vg
.N
Er
ro
r
Po
w
er
A
vg
.N
Er
ro
r
Po
w
er
A
vg
.N
Er
ro
r
Po
w
er
A
vg
.N
C
1
0.
36
5
-
86
0.
06
-
17
5
0
-
50
3
0
-
55
1
C
2
5.
14
5
-
86
2.
67
5
-
17
5
0.
08
5
-
49
3
0
-
57
2
C
3
8.
43
5
-
86
4.
17
5
-
17
5
0.
09
5
-
49
1
0.
00
5
-
54
9
C
4
11
.0
55
-
86
5.
46
5
-
17
5
0.
20
5
-
49
3
0.
00
5
-
57
2
C
5
0.
09
25
.4
86
0.
01
25
.0
35
17
6
0
7.
22
49
9
0
0.
58
5
56
8
C
6
2.
22
5
23
.7
7
86
1.
22
23
.2
7
17
5
0.
03
6.
40
5
49
3
0
0.
49
53
9
C
7
4.
00
5
22
.7
75
86
1.
98
22
.0
9
17
6
0.
04
6.
14
5
49
6
0
0.
56
54
5
C
8
0.
01
5
33
.3
1
86
0
32
.8
3
17
5
0
8.
61
5
48
7
0
0.
61
5
56
3
C
9
1.
33
5
31
.5
8
86
0.
69
5
31
.0
4
17
5
0.
01
8.
09
49
9
0.
00
5
0.
56
5
57
0
Table A.6: Misspecified Smaller True Effect Size: Unadjusted Stage
One, Unadjusted Stage Two
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Table A.7: Misspecified Smaller True Effect Size: Bonferroni Ad-
justed Stage One, Unadjusted Stage Two
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Table A.8: Misspecified Smaller True Effect Size: Bonferroni Ad-
justed Stage One, Bonferroni Adjusted Stage Two
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Table A.9: Misspecified Smaller True Effect Size: Hochberg Adjusted
Stage One, Unadjusted Stage Two
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Table A.10: Misspecified Smaller True Effect Size: Hochberg Ad-
justed Stage One, Bonferroni Adjusted Stage Two
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APPENDIX B
Appendix B: Figures
B.1 CHAPTER FOUR ADDITIONAL FIGURES
B.1.1 Alternate Placebo Effect Size Error Figures
Figure B.1: C1 UU FWER Figure B.2: C1 BU FWER
Figure B.3: C1 BB FWER Figure B.4: C1 HU FWER
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Figure B.5: C1 HB FWER Figure B.6: C2 UU FWER
Figure B.7: C2 BU FWER Figure B.8: C2 BB FWER
Figure B.9: C2 HU FWER Figure B.10: C2 HB FWER
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Figure B.11: C3 UU FWER Figure B.12: C3 BU FWER
Figure B.13: C3 BB FWER Figure B.14: C3 HU FWER
Figure B.15: C3 HB FWER
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B.1.2 Alternate Placebo Effect Size Power Figures
Figure B.16: C5 UU Power Figure B.17: C5 BU Power
Figure B.18: C5 BB Power Figure B.19: C5 HU Power
Figure B.20: C5 HB Power Figure B.21: C6 UU Power
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Figure B.22: C6 BU Power Figure B.23: C6 BB Power
Figure B.24: C6 HU Power Figure B.25: C6 HB Power
Figure B.26: C8 UU Power Figure B.27: C8 BU Power
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Figure B.28: C8 BB Power Figure B.29: C8 HU Power
Figure B.30: C8 HB Power Figure B.31: C9 UU Power
Figure B.32: C9 BU Power Figure B.33: C9 BB Power
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Figure B.34: C9 HU Power Figure B.35: C9 HB Power
B.1.3 True Effect Size Bigger Than Assumption Error Figures
Figure B.36: C1 UU FWER Figure B.37: C1 BU FWER
Figure B.38: C1 BB FWER Figure B.39: C1 HU FWER
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Figure B.40: C1 HB FWER Figure B.41: C2 UU FWER
Figure B.42: C2 BU FWER Figure B.43: C2 BB FWER
Figure B.44: C2 HU FWER Figure B.45: C2 HB FWER
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Figure B.46: C3 UU FWER Figure B.47: C3 BU FWER
Figure B.48: C3 BB FWER Figure B.49: C3 HU FWER
Figure B.50: C3 HB FWER
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B.1.4 True Effect Size Bigger Than Assumption Power Figures
Figure B.51: C5 UU Power Figure B.52: C5 BU Power
Figure B.53: C5 BB Power Figure B.54: C5 HU Power
Figure B.55: C5 HB Power Figure B.56: C6 UU Power
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Figure B.57: C6 BU Power Figure B.58: C6 BB Power
Figure B.59: C6 HU Power Figure B.60: C6 HB Power
Figure B.61: C8 UU Power Figure B.62: C8 BU Power
162
Figure B.63: C8 BB Power Figure B.64: C8 HU Power
Figure B.65: C8 HB Power Figure B.66: C9 UU Power
Figure B.67: C9 BU Power Figure B.68: C9 BB Power
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Figure B.69: C9 HU Power Figure B.70: C9 HB Power
B.1.5 True Effect Size Smaller Than Assumption Power Figures
Figure B.71: C3 UU Power Figure B.72: C3 BU Power
Figure B.73: C3 BB Power Figure B.74: C3 HU Power
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Figure B.75: C3 HB Power Figure B.76: C4 UU Power
Figure B.77: C4 BU Power Figure B.78: C4 BB Power
Figure B.79: C4 HU Power Figure B.80: C4 HB Power
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Figure B.81: C5 UU Power Figure B.82: C5 BU Power
Figure B.83: C5 BB Power Figure B.84: C5 HU Power
Figure B.85: C5 HB Power Figure B.86: C6 UU Power
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Figure B.87: C6 BU Power Figure B.88: C6 BB Power
Figure B.89: C6 HU Power Figure B.90: C6 HB Power
Figure B.91: C7 UU Power Figure B.92: C7 BU Power
167
Figure B.93: C7 BB Power Figure B.94: C7 HU Power
Figure B.95: C7 HB Power Figure B.96: C8 UU Power
Figure B.97: C8 BU Power Figure B.98: C8 BB Power
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Figure B.99: C8 HU Power Figure B.100: C8 HBPower
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APPENDIX C
Appendix C: SAS and Unix Code
Full SAS and Unix computing cluster code is available via Dropbox link upon re-
quest to egurary@bu.edu.
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